Genome wide association analysis in dilated cardiomyopathy reveals two new key players in systolic heart failure on chromosome 3p25.1 and 22q11.23

Sophie Garnier^{1,2*}, Magdalena Harakalova^{3,4}, Stefan Weiss^{5,6}, Michal Mokry^{3,7,8}, Vera Regitz-Zagrosek^{9,10}, Christian Hengstenberg^{11,12}, Thomas P Cappola¹³, Richard Isnard^{1,2,14}, Eloisa Arbustini¹⁵, Stuart A. Cook¹⁶⁻¹⁸, Jessica van Setten³, Jörg Callis^{3,4}, Hakon Hakonarson¹⁹, Michael P Morley¹³, Klaus Stark²⁰, Sanjay K. Prasad^{17,21}, Jin Li¹⁹, Declan P O'Regan²², Maurizia Grasso²³, Martina Müller-Nurasyid²⁴⁻²⁶, Thomas Meitinger^{24,25,27}, Jean-Philippe Empana²⁸, Konstantin Strauch^{24,25,29}, Mélanie Waldenberger^{30,31}, Kenneth B Marguiles¹³, Christine E. Seidman^{32,33}, Benjamin Meder³⁴, Pierre Boutouyrie^{28,35}, Patrick Lacolley³⁶, Xavier Jouven^{28,35}, Jeanette Erdman³⁷, Stefan Blankenberg³⁸, Thomas Wichter³⁹, Volker Ruppert⁴⁰, Luigi Tavazzi⁴¹, Olivier Dubourg⁴², Gerard Roizes⁴³, Richard Dorent⁴⁴, Pascal DeGroot⁴⁵, Laurent Fauchier⁴⁶, Jean-Noël Trochu^{47,48}, Jean-François Aupetit⁴⁹, Marine Germain⁵⁰, Uwe Völker^{5,6}, Hemerich Daiane³, Ibticem Raji⁵¹, Delphine Bacq-Daian^{52,53}, Carole Proust⁵⁰, Kristin Lehnert^{6,54}, Renee Maas^{3,4}, Robert Olaso^{52,53}, Ganapathivarma Saripella^{1,55}, Stephan B. Felix^{6,54}, Steven Mc Ginn^{52,53}, Laëticia Duboscq-Bidot^{1,2,14}, Alain van Mil^{3,4}, Céline Besse^{52,53}, Vincent Fontaine^{1,2}, Hélène Blanché^{53,56}, Brendan Keating⁵⁷, Pablo Garcia-Pavia^{58,59#}, Angélique Curjol⁵¹, Anne Boland^{52,53}, Michel Komajda^{1,2,60}, François Cambien⁵⁰, Jean-François Deleuze^{52,53,56}, Marcus Dörr^{6,54}, Folkert W Asselbergs^{3,61,62}, Eric Villard^{1,2,14\$}, David-Alexandre Tréguët^{50\$} and Philippe Charron^{1,2,14,51#*\$. On behalf of GENMED consortium.}

Affiliations:

1. Sorbonne Université, INSERM, UMR-S1166, research unit on cardiovascular disorders, metabolism and nutrition, Team Genomics & Pathophysiology of Cardiovascular Diseases, F-75013, Paris, France.
2. ICAN Institute for Cardiometabolism and Nutrition, F-75013, Paris, France.
3. Department of Cardiology, Division Heart & Lungs, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands

4. Regenerative Medicine Center, University Medical Center Utrecht, Utrecht, the Netherlands
5. Interfaculty Institute for Genetics and Functional Genomics, Department of Functional Genomics, University Medicine Greifswald, Greifswald, Germany
6. DZHK (German Centre for Cardiovascular Research), partnersite Greifswald, Greifswald, Germany
7. Laboratory of Clinical Chemistry and Haematology, University Medical Center, Heidelberglaan 100, Utrecht, The Netherlands
8. Laboratory of Experimental Cardiology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, The Netherlands
9. Institute of Gender in Medicine and Center for Cardiovascular Research, Charite University Hospital, Berlin, Germany
10. DZHK (German Center for Cardiovascular Research), Berlin, Germany
11. Department of Internal Medicine, Division of Cardiology, Medical University of Vienna, Austria
12. Department of Internal Medicine, Medical University of Regensburg, Germany
13. Penn Cardiovascular Institute and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
14. APHP, Pitié-Salpêtrière Hospital, Cardiology Department, Paris, France
15. IRCCS Fondazione Policlinico San Matteo, Pavia, Italy.
16. National Heart and Lung Institute, Imperial College London, London, UK.
17. National Heart Centre Singapore, Singapore.
18. Duke-NUS, Singapore.
19. Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, USA.
20. Department of Genetic Epidemiology, University of Regensburg, Regensburg, Germany.

21. Royal Brompton Hospital, London, UK
22. Medical Research Council Clinical Sciences Centre, Faculty of Medicine, Imperial College London, London, UK
23. Centre for Inherited Cardiovascular Diseases - IRCCS Fondazione Policlinico San Matteo, Pavia, Italy
24. Institute of Genetic Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany
25. Chair of Genetic Epidemiology, IBE, Faculty of Medicine, LMU Munich, Germany.
26. Department of Internal Medicine I (Cardiology), Hospital of the Ludwig-Maximilians-University (LMU) Munich, Munich, Germany
27. Institute of Human Genetics, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
28. Université de Paris, INSERM, UMR-S970, Integrative Epidemiology of cardiovascular disease, Paris, France
29. Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center, Johannes Gutenberg University, 55101 Mainz, Germany
30. Research unit of Molecular Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany
31. DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany
32. Department of Medicine and Genetics Harvard Medical School, Boston, USA.
33. Brigham & Women's Cardiovascular Genetics Center, Boston, USA.
34. Institute for Cardiomyopathies Heidelberg, Heidelberg University, Germany & Stanford Genome Technology Center, Department of Genetics, Stanford Medical School, California, USA

35. APHP, Georges Pompidou European Hospital, Cardiology Department, Paris, France
36. INSERM U1116, Faculté de Médecine, Vandoeuvre-les-Nancy, Paris, France
37. Medizinische Klinik und Poliklinik, Universitätsmedizin der Johannes-Gutenberg Universität Mainz, Mainz, Germany
38. Medizinische Klinik II, Universität Lübeck, Lübeck, Germany
39. Dept. of Cardiology and Angiology Niels-Stensen-Kliniken Marienhospital Osnabrück, Heart Centre Osnabrück / Bad Rothenfelde, Dept. of Cardiology and Angiology, D-49074, Osnabrück, Germany
40. Klinik für Innere Medizin-Kardiologie UKGM GmbH Standort Marburg Baldingerstrasse, Marburg, Germany
41. Maria Cecilia Hospital, GVM Care and Research, Cotignola, Italy
42. Université de Versailles-Saint Quentin, Hôpital Ambroise Paré, AP-HP, Boulogne, France
43. Institut de Génétique Humaine, UPR 1142, CNRS, Montpellier, France
44. Service de Cardiologie, CHU Tenon, Paris, France
45. Service de Cardiologie, Hôpital Cardiologique, Lille, France
46. Service de Cardiologie, Centre Hospitalier Universitaire Trousseau, Tours, France
47. INSERM UMR915, l'institut du thorax, Nantes, France
48. CHU Nantes, Service de Cardiologie, Nantes, France
49. Département de pathologie cardiovasculaire, Hôpital Saint-Joseph-Saint-Luc, Lyon, France
50. INSERM UMR_S 1219, Bordeaux Population Health Research Center, University of Bordeaux, Bordeaux, France

51. AP-HP, Département de génétique, Centre de Référence Maladies Cardiaques Héritaires, Hôpital Pitié-Salpêtrière, Paris, France.

52. Centre National de Recherche en Génomique Humaine (CNRGH), Institut de Biologie François Jacob, CEA, Université Paris-Saclay, F-91057, Evry, France

53. Laboratory of Excellence GENMED (Medical Genomics)

54. Department of Internal Medicine B, University Medicine Greifswald, Greifswald, Germany

55. SLU Bioinformatics Infrastructure (SLUBI), PlantLink, Department of Plant Breeding, Swedish University of Agricultural Sciences, Alnarp, Sweden (current affiliation)

56. Centre d'Etude du Polymorphisme Humain, Fondation Jean Dausset, Paris, France

57. Division of Transplantation, Departments of Surgery, University of Pennsylvania, Philadelphia, the United States

58. Department of Cardiology, Hospital Universitario Puerta de Hierro, CIBERCV, Madrid, Spain

59. Universidad Francisco de Vitoria (UFV), Pozuelo de Alarcón, Spain

60. Cardiology Department, Groupe Hospitalier Paris Saint Joseph, Paris, France

61. Institute of Cardiovascular Science, Faculty of Population Health Sciences, University College London, London, United Kingdom

62. Health Data Research UK and Institute of Health Informatics, University College London, London, United Kingdom

[#]Member of European Reference Networks for rare, low prevalence and complex diseases of the heart (ERN GUARD-Heart)

[§] These authors equally contributed to the work

*Corresponding authors: Sophie Garnier (sophie.garnier@sorbonne-universite.fr); tel +33 (0)1 40 77 81 40; fax +33 (0)1 40 77 97 28 and Philippe Charron (philippe.charron@aphp.fr)

Summary

We present the results of the largest genome wide association study (GWAS) performed so far in dilated cardiomyopathy (DCM), a leading cause of systolic heart failure and cardiovascular death, with 2,719 cases and 4,440 controls in the discovery population. We identified and replicated two new DCM-associated loci, one on chromosome 3p25.1 (lead SNP rs62232870, $p = 8.7 \times 10^{-11}$ and 7.7×10^{-4} in the discovery and replication step, respectively) and the second on chromosome 22q11.23 (lead SNP rs7284877, $p = 3.3 \times 10^{-8}$ and 1.4×10^{-3} in the discovery and replication step, respectively) while confirming two previously identified DCM loci on chromosome 10 and 1, *BAG3* and *HSPB7*. The genetic risk score constructed from the number of lead risk-alleles at these four DCM loci revealed that individuals with 8 risk-alleles were at a 27% increased risk of DCM compared to individuals with 5 risk alleles (median of the referral population). We estimated the genome wide heritability at $31\% \pm 8\%$.

In silico annotation and functional 4C-sequencing analysis on iPSC-derived cardiomyocytes strongly suggest *SLC6A6* as the most likely DCM gene at the 3p25.1 locus. This gene encodes a taurine and beta-alanine transporter whose involvement in myocardial dysfunction and DCM is supported by recent observations in humans and mice. Although less easy to discriminate the better candidate at the 22q11.23 locus, *SMARCB1* appears as the strongest one.

This study provides both a better understanding of the genetic architecture of DCM and new knowledge on novel biological pathways underlying heart failure, with the potential for a therapeutic perspective.

Keywords: Dilated Cardiomyopathy, GWAS, 4C-sequencing, Heritability, Genetic Risk Score

Introduction

Dilated cardiomyopathy (DCM) is a heart muscle disease characterized by left ventricular dilatation and systolic dysfunction in the absence of abnormal loading conditions or coronary artery disease (CAD)(1,2). It is a major cause of systolic heart failure, the leading indication for heart transplantation, and therefore a major public health problem due to the important cardiovascular morbidity and mortality(1,2). The understanding of the genetic basis of DCM has improved during the past years with the role of both rare and common variants resulting in a complex genetic architecture of the disease(3,4). More than 50 genes(4–6) with rare pathogenic mutations have been reported as causing DCM, mainly inherited as dominant with variable penetrance. Several large scale association studies in sporadic cases have been performed to identify common DCM-associated alleles(7–13) including four genome wide association studies (GWAS)(9,10,12,13). Altogether, these genetic investigations have so far robustly identified 2 loci harboring common susceptibility alleles: a locus on chromosome 1, encompassing multiple candidate genes in strong linkage disequilibrium (LD), including *ZBTB17/MIZ-1*, *HSPB7* and *CLCNKA*(7–12); and a second locus on chromosome 10 for which the culprit gene, *BAG3*, is also involved in familial forms of DCM(9,14). The analysis of 116,855 common coding variants in an exome wide association study (EWAS) has also suggested the existence of six potential additional DCM loci(11) but, in absence of proper replication, their true contribution to DCM has not been definitively established. Here, we report the results of a new GWAS for sporadic DCM performed on 2,719 cases and 4,440 controls. Individual genotype data were imputed for the 1000Genomes reference panel and the main findings replicated in two independent case-control samples totaling 584 cases and 986 controls. Then, *in silico* annotation and functional analyses were performed in candidate loci to identify the

better candidates. We also estimated the global genetic heritability, and built a genetic risk score (GRS) for DCM.

Material and Methods

Populations inclusion and samples collection

DCM patients and controls from five populations (France, Germany, USA, Italy and UK) were included in the GWAS (a detailed description of the cohorts is provided in **Supplemental Material**). Sporadic DCM was diagnosed according to standard criteria(1,4,15,16) by reduced ejection fraction (EF, echocardiography: <45% or MRI: <2 standard deviations (SDs) below the age- and sex-adjusted mean (16)) and an enlarged left ventricle end-diastolic volume/diameter (LVEDD >117% of value predicted from age and body surface area on echocardiography, or >2 SDs from the age- and sex-adjusted mean by MRI(16)) in the absence of significant coronary artery disease or intrinsic valvular disease, documented myocarditis, systemic disease, sustained arterial hypertension, or congenital malformation. All patients signed informed consent and the study protocol was approved by local ethics committees. In total, 2,719 cases and 4,440 controls were included in the discovery GWAS analysis.

Two case-control samples were available for replication of the main discovery GWAS findings, a Dutch population composed of 145 DCM cases and 527 controls(17) and a German collection of 439 patients with left ventricle dilation and/or hypokinetic non-dilated cardiomyopathy (HNDC) and 439 controls(18,19) (detailed descriptions are provided in **Supplemental Material**).

Genotyping, genotype calling, and imputation

Genotyping was performed with high-density arrays for all samples and was further imputed with the 1,000 Genomes reference dataset. Summary descriptions of specific genotyping

arrays, QC filtering, and imputation methods are given in **Supplemental Material** and **Supplementary Table 1**.

Association analysis in the discovery phase

Association of imputed SNPs with DCM was performed using the Mach2dat software(20,21) implementing a logistic regression model adjusted for sex and genome-wide genotype-derived principal components under the assumption of additive allele effects. Only bi-allelic SNPs with imputation quality, r^2 , greater than 0.5 and minor allele frequency (MAF) higher than 0.005 were kept for association analysis. A statistical threshold of 5×10^{-8} was used to declare genome-wide significance.

To check the existence of several independent DCM-associated SNPs at loci with genome-wide statistical significance, we conducted conditional analyses adjusting for the lead SNP at each identified locus. In the case of more than one significant SNP at a given locus, additional haplotype analyses were conducted using the THESIAS software(22).

Association analysis in the replication phase

SNPs selected for replication were tested using the same statistical model as that used in the discovery stage, separately in each of the two replication cohorts, adopting a one-tailed hypothesis and applying a Bonferroni correction procedure to declare statistical replication while controlling for the number of tested SNPs. Results of the replication studies were subsequently meta-analyzed using a fixed-effects model based on the inverse-weighting method as implemented in the Metal software(23). A similar meta-analysis framework was applied to combine the results of the discovery and replication phase. Heterogeneity across

studies (between the two replication studies or between the discovery and replication stage) was tested using the Cochran's Q statistic and the I^2 index was used to express its magnitude.

Regional association plot

At each of the replicated associated genetic loci, a regional association plot was performed using the LocusZoom online tool (<http://locuszoom.sph.umich.edu/>).

Genetic risk score analysis

A genetic risk score (GRS) was built upon the two SNPs already known to associate with DCM, *HSPB7*-rs10927886(7–12) and *BAG3*-rs2234962(9,14) and the independent replicated genome-wide significant DCM associated SNPs. That score was tested, using logistic regression analysis, for association with DCM on a continuous scale and with quintile repartition. For each individual i , the GRS was defined as $GRS_i = \sum_{k=1}^K \beta_k G_{ik}$, where K is the number of variants composing the score, β_k is the log-odds ratio for DCM associated with variant k obtained in the replication phase and G_{ik} is the allele dosage at variant k for individual i .

Genetic heritability

The linkage disequilibrium (LD) score regression approach(24) was used to get an estimate of the genome-wide genetic heritability underlying DCM. We also used this methodology to calculate the genetic correlation between DCM and several cardiovascular traits capitalizing on the GWAS results available at the LD Hub (<http://ldsc.broadinstitute.org/ldhub/>).

Candidates selection strategy at associated loci

For each newly identified DCM locus, a downstream fine-mapping strategy was deployed using *in silico* and experimental functional data to select the best candidates at each locus.

Cis-regulation of associated SNPs

At each locus, DCM associated SNPs ($p\text{-value} \leq 5 \times 10^{-8}$ and/or presenting a high LD ($r^2 > 0.7$) with the lead SNP) were used to define the associated “LD block”. We checked whether those blocks could overlap with DNA regulatory elements by using the UCSC Genome Browser(25) in human assembly hg19 (<http://genome.ucsc.edu/>) by visualizing the ENCODE3 DNase hypersensitivity sites (DHS)(26) and transcription factor (TF) chromatin immunoprecipitation sequencing (ChIP-seq)(27) tracks produced on 125 and 130 cell lines, respectively. To detect left ventricle (LV)-specific putative regulatory regions we enriched those tracks with H3K27ac (active chromatin), H3K4me1 (enhancer) and H3K4me3 (promotor) histone marks of ENCODE heart LV samples (GSM910575, GSM910580, GSM908951)(28). To support the potential regulatory/promotor role of those regions, we looked at regulatory elements predicted from ORegAnno(29) and checked sequence conservation in a subset of the vertebrates(30).

Topologically associating domains (TAD) and intra-TAD chromatin interactions

TADs are domains of preferential chromatin interaction separated by insulators where genes are accessible to intra-TAD regulatory elements, such as enhancers(31). Taking advantage of public resources describing those TADs, we delimited the region comprising the LD block, thus the subset of candidate genes, that are jointly regulated. Regional candidate genes were defined based on published LV TADs described in Leung *et al.*(28), as well as preferential chromatin interaction measured *via* promoter chromatin Hi-C (PCHi-C) on iPSC-derived cardiomyocytes (iPSC-CM) by Montefiori *et al.*(32).

Those published TAD boundaries were confirmed by in-house circular chromatin conformation capture (4C)-sequencing data produced on an iPSC-derived cardiomyocyte line from a donor (a full description is enclosed in the **Supplemental Material**).

Candidate genes' biological insights

The heart expression level of each candidate gene in an associated region was evaluated *via* RNA-sequencing cardiac expression data issued from the Genotype-Tissue Expression (GTEx) project database²² (<http://www.gtexportal.org/home/>) (LV and atrial appendage) and from LV explants of DCM cases and controls produced by Henig *et al.*(33). That later work also enabled us to check whether differential expression existed between the 97 DCM patients and the 108 healthy donors. For the subset of gene displaying interesting expression features, we then scrutinized publicly available resources for gene annotation and functions.

Annotation of associated SNPs

The annotation of SNPs' blocks was realized with Annovar software(34) and bioinformatics prediction of effects using RegulomeDB(35), Regulatory Mendelian mutation (ReMM)(36) and the GRCh37-v1.4 Combined Annotation Dependent Depletion (CADD) model(37) (<https://cadd.gs.washington.edu/snv>). Each SNP of an association block being prone to be implicated in an alteration of local regulatory function, we went through various *in silico* data in an effort to identify regulatory ones. We thus screened GTEx database for expression and splicing quantitative trait loci (eQTL and sQTL) in human cardiac and skeletal muscle tissues, checked whether some of those SNPs could be associated with blood DNA methylation levels (mQTL)(38) and looked at their location in putative enhancer or promotor region (H3K27ac, H3K4me1, and H3K4me3 histone marks).

Results

Main statistical findings

After quality controls, 9,152,885 SNPs (including 8,945,131 autosomal and 207,754 X chromosome SNPs) were tested for association with DCM in a total of 2,651 cases and 4,329 controls. Results of the discovery GWAS are summarized in a Manhattan and a Quantile-Quantile plot (**Figure 1** and **Supplementary Figure 1**). The main findings are summarized in **Table 1**. Five loci reached genome-wide significance. Two were already known to associate with DCM, *BAG3* ($p = 4.7 \times 10^{-14}$ for rs61869036) and *HSPB7* ($p\text{-value} = 2.12 \times 10^{-13}$ for rs10927886). Of note, the *BAG3* rs61869036 is in complete LD ($r^2 \sim 1$) with the nonsynonymous rs2234962 already reported to associate with DCM(9,11) that was thus further used as *BAG3* lead SNP ($p = 5.6 \times 10^{-14}$). Three new loci reached genome-wide significance on chr3p25.1 (rs62232870, $p = 8.7 \times 10^{-11}$) downstream *LSM3*, on chr16p13.3 (*PKD1* rs2519236, $p = 3.0 \times 10^{-8}$) and on chr22q11.23 (*SMARCB1* rs7284877, $p = 3.3 \times 10^{-8}$). Regional association plots at these 5 loci are shown in **Supplementary Figures 2-6**.

Conditional GWAS adjusted for the 5 lead SNPs did not reveal any new genome-wide association signal (**Supplementary Figure 7 and 8**).

At chr3p25 locus, a second SNP, rs4684185, showed a strong statistical association ($p = 8.4 \times 10^{-9}$) and is in negative LD ($r^2 = 0.12$, $D' = -0.95$) with the lead rs62232870. While the rs62232870-A allele with frequency ~ 0.21 was associated with an increased OR for DCM of 1.36 [1.24 - 1.49], the common rs4684185-C allele with frequency ~ 0.70 was associated with an OR of 1.28 [1.17 - 1.40]. After adjusting on rs62232870 lead SNP, the association of rs4684185 is no longer significant but a residual signal remained ($p = 5.10^{-4}$) suggesting a more complex

interaction. A detailed haplotype analysis of these SNPs (**Supplementary Table 2**) showed that, compared to the most frequent rs62232870-G/rs4684185-C haplotype, the rs62232870-A/rs4684185-C haplotype was associated with an increased risk of DCM (OR = 1.22 [1.11 – 1.33]) while its yin-yang haplotype defined by the rs62232870-G/rs4684185-T alleles was protective against DCM (OR = 0.82 [0.76 – 0.89]).

We sought to replicate the observed associations at chromosome 3, 16 and 22 loci in two independent studies totaling 584 DCM patients and 966 controls. The *PKD1* rs148248535 did not show any statistical evidence for replication ($p = 0.11$) but we confirmed the associations observed at chr3p25.1 ($p = 7.70 \cdot 10^{-4}$ and $p = 6.10 \cdot 10^{-3}$ for rs62232870 and rs4684185, respectively), including the yin-yang haplotype association (**Supplementary Table 2**), and at chr22q11.23 ($p = 1.40 \cdot 10^{-3}$ for rs7284877) (**Table 1**).

In a combined meta-analysis of the discovery and replication findings, the resulting ORs for DCM were 1.36 [1.25 - 1.48] ($p = 5.3 \cdot 10^{-13}$) and 1.27 [1.18 - 1.37] ($p = 4.8 \cdot 10^{-10}$) for chr3p25.1 rs62232870 and rs4684185, respectively and 1.33 [1.22 - 1.46] ($p = 5.0 \cdot 10^{-10}$) for chr22q11.23 *SMARCB1* rs7284877, with no evidence for heterogeneity across studies (**Table 1**).

Genetic risk score analysis

We built both an unweighted and a weighted genetic risk score (GRS) using the 4 lead SNPs at the two already known loci (*BAG3* and *HSPB7*) and those at the two replication loci, chr3p25.1 (rs62232870) and chr22q11.23 (rs7284877).

GRS findings are summarized in **Figure 2A and B** and **Table 2A and 2B**. Briefly, the risk of DCM in the discovery cohort for the unweighted GRS (**Table 2A**) was increased by 27% for the subjects with 8 risk alleles (1.27 [1.14-1.42]) and decreased by 21% for those having only one

risk allele (0.79 [0.66-0.95]) as compared with the 5 risk alleles reference group (**Figure 2A**). Similar results are found for the weighted GRS (30% increase (1.30 [1.16-1.45]) and 19% decreased (0.81 [0.67-0.97] for those having the lowest and highest score as compared with the 1.6 score reference group (**Figure 2B**). An OR increase with each risk allele increment is still visible, but not significant, in the replication cohorts (**Supplementary Table 3**). To improve size homogeneity between the groups, a quintile repartition was also realized (**Supplementary Figure 9**).

Heritability

Using our GWAS summary statistics, the estimated genome-wide DCM heritability in our European populations was around 31% $\pm$ 8.4. We also examined the genetic correlation between DCM and various cardiovascular traits (e.g. coronary artery disease, heart diseases) but did not observe much shared genetic heritability. The strongest genetic correlation was observed with lipid- and obesity-related traits, e.g. waist circumference ($\rho = 0.47$, $p = 3.2 \cdot 10^{-8}$), whole-body mass fat ($\rho = 0.46$, $p = 6 \cdot 10^{-8}$), or adiponectin ($\rho = 0.38$, $p = 7 \cdot 10^{-6}$).

Candidate culprit gene selection strategy at chr3p25.1

As shown in **Figure 3A**, the top SNP, rs62232870, is located at the edge of an active enhancer region lying distal to *LSM3* as evidenced by H3K27ac and H3K4me3 histone marks from ENCODE human LV samples (GSM910575, GSM910580, GSM908951). Of note, this enhancer region is absent from the seven default ENCODE non-cardiomyocyte cell lines suggesting cardiac tissue-specific expression. Other remarkable features support this region as regulatory active, such as significant sequence conservation in a subset of vertebrates, predicted

regulatory elements from ORegAnno, hypersensitive sites for DNaseI, and multiple transcription factor (TF) chromatin immunoprecipitation sequencing (ChIP-seq).

The associated block of SNPs covers ~50kb [chr3:14,257,356-14,307,016] overlapping with another partially independent block of SNPs (in LD with the second lead SNP rs4684185, $r^2 > 0.87$) (**Supplementary Figure 3** and **Supplementary Table 4**) where predicted LV H3K27ac and H3K4me1 enhancer marks, reported by Leung *et al.*(28), are present. It is located in a clearly delimited TAD spanning [chr3:14,160,000-14,680,000] (**Figure 4Ab**) which encompasses 6 genes (*CHCHD4*, *TMEM43*, *XPC*, *LSM3*, *SLC6A6* and *GRIP2*) (**Supplementary Table 5**) whose promoters interact with H3K27ac/H3K4me1 enhancer marks in iPSC-CM (**Figure 4Af**). Interestingly, promoter Hi-C data analysis revealed specific interactions of *SLC6A6* and *GRIP2* promoters with the chr3p25.1 lead SNP bait.

The 4C-seq results from in-house iPSC-CM cell lines presented in **Figure 4Ag**, show more extended significant interaction ($p < 10^{-8}$) between the associated region bait [chr3:14,257,356-14,307,016] and intra-TAD regional promoters, confirming TAD boundaries and enhancer function of the chromosome 3p25.1 locus. The strongest interaction signals (dark blue scale figure 4Ag; $p < 10^{-50}$, **Supplementary Table 6**) are localized on *SLC6A6*, *XPC/LSM3* region as well as in the intergenic region between those two genes where the bait is localized. Several baits specific of the 4C region and interacting with the associated SNPs block were designed to test for reverse interactions and confirmed the specificity of those *cis*-interaction signals (data not shown).

For each **Supplementary Table 5** positional candidate gene, we filtered out the intra-TAD better candidates based on cardiac expression data from GTEx, Montefiori *et al.*(32) and Henig *et al.*(33) as well as publicly available resources for gene annotation.

Looking at LV and atrial appendage expression, all those genes are expressed with from the most to the less expressed *TMEM43*, *CHCHD4*, *LSM3*, *SLC6A6*, *XPC* and *GRIP2* (**Supplementary Table 7A**). Moreover, *XPC* ($p = 8.3 \cdot 10^{-15}$) and *SLC6A6* ($p = 6.9 \cdot 10^{-6}$) LV expressions were significantly increased in DCM patients compared to healthy donors (**Supplementary Table 7A**) while *LSM3* expression was significantly decreased ($p = 7.6 \cdot 10^{-8}$). Functional candidate at this locus may include *TMEM43*, implied in arrhythmogenic right ventricular cardiomyopathy (ARVC)(39–41), and *SLC6A6*, for which a homozygous deletion affecting a splice site was found by whole-exome sequencing in a patient with idiopathic DCM(42).

Among the associated SNPs' block, we then screened the GTEx database and Lemire *et al* results for eQTL, sQTL and mQTL(38). Even though we did not observe any evidence that the lead SNP, rs62232870, could influence the expression of nearby genes in relevant heart and skeletal muscle tissues, **Table 3** presents DCM associated SNPs, in moderate LD, associated with *SLC6A6* expression in heart atrial appendage. For example, rs7612736 ($r^2 = 0.71$, $D' = 0.90$, association p-value $1.6 \cdot 10^{-9}$) moderately associates with that gene expression ($p = 5.8 \cdot 10^{-5}$). No sQTL was present but all the SNPs are associated with methylation level of several neighbor genes (**Table 4**). rs62232870 and the SNPs in strong LD with it are strongly associated with the methylation level of CpG site in *SLC6A6* and *TMEM43* (cg08926287 and cg15025640 with p-value around 10^{-30} and 10^{-16} , respectively) while the rs4684185 LD SNP block associates primarily with *SLC6A6* and *XPC* methylation levels (cg08926287 and cg23070574 with p-value around 10^{-70} and 10^{-36} , respectively).

Combining all the data available so far (**Table 4**), the best candidate to take shape at this locus is *SLC6A6* which is expressed in heart, differently between DCM and controls, and for which associated SNPs modulates methylation and expression (mQTLs and eQTLs).

Candidate culprit gene selection strategy at chr22q11.23 locus

The LD block of DCM-associated SNPs (**Supplementary Figure 6 - Supplementary Table 4**) extends over 70kb from the 5' region of *MMP11* and *CHCHD10* to the 5' region of *DERL3* including *SMARCB1* where the lead SNP maps to [chr22:24,110,180-24,182,174]. Multiple features witnessing the regulatory role of that locus, including LV enhancers(28), are observed (**Figure 3B**) and published ChIP-Seq experiments demonstrate that it is also strongly associated with H3K27ac and H3K4me1 LV marks (**Figure 3B**) providing support for an active enhancer function of that locus. TAD analysis at chromosome 22 showed that the associated SNPs block is located at the edge of 2 CM predicted TADs covering 1.2Mb [chr22:23,480,001-24,680,000] (**Figure 4B**). As multiple and strong intra- and inter-TADs interactions are found in that region (**Figure 4B**), the 21 genes covered by the two TADs should be considered as positional candidates (**Supplementary Table 5**).

Cardiomyocytes 4C-seq using the bait at chromosome 22 associated region revealed strong interactions with enhancer (H3K27ac/H3K4me1 positive) elements located close by (*SMARCB1*, *DERL3*, *MMP11*, *SLC2A11*, and *CHCHD10* principally), and to a lesser extent with the *BCR* gene locus and an intergenic 50kb 3' of *IGLL1* and 18kb 3' of *RGL4* and with the promoter rich region adjacent to the bait up to *CABIN1* (**Figure 4Bd-f**). The strongest 4C interaction signals (**Figure 4Bg**), are found for *SMARCB1* and *DERL3* (**Supplementary Table 8**; $p < 10^{-50}$). Reverse interactions were tested with several baits confirming the specificity of those *cis*-interaction signals (data not shown).

Cardiac expression data showed that the most strongly expressed gene was *CHCHD10* (**Supplementary Table 7B**) followed by *GSTT1*, *DDT* and *SMARCB1* and, to a lesser extent, *CABIN1* and *SLC2A11*. The other 15 genes (*MIF*, *ZNF70*, *DERL3*, *MMP11* and further genes)

appeared to be lower or not expressed. In LV tissue, *CHCHD10* and to a lesser extent *DDT*, *SMARCB1*, *SLC2A11*, and *CABIN1* were found to be differentially expressed between DCM and healthy donors (**Supplementary Table 7B**).

Among the association block, eQTL and sQTL were checked in GTEx database. **Table 3** presented the significant eSNP in relevant cardiac and skeletal tissues. From these 6 candidate genes, only *SMARCB1* expression was observed to be consistently strongly influenced by DCM associated SNPs, including the lead rs7284877 in the heart (**Supplementary Figure 10**) and skeletal muscle tissues. Three other genes, *MMP11*, *VPREB3*, and *DERL3*, even though not strongly expressed in heart, are also influenced by those associated SNPs in heart and/or skeletal muscle tissues (**Table 3**). No sQTL was present but rs7284877 and the SNPs in LD with it are associated with methylation level variation of several nearby genes (**Table 4**). The strongest regulation signals are detected for *SMARCB1* and *DERL3* (cg08219923 and cg25907215) with the best p-values below 10^{-200} .

Combining all the data available so far (**Table 4**), *SMARCB1* that is expressed in heart, differentially in DCM and control heart explants and for which associated SNPs modulates methylation and expression (mQTLs and eQTLs) appears to be the strongest candidate.

Discussion

By adopting a GWAS strategy, performed in the largest population of DCM assembled so far, we identified and replicated two new susceptibility loci for DCM while confirming two previously reported DCM associated ones, *HSPB7* and *BAG3*.

The first novel locus maps to chr3p25.1 where the minor A allele of the lead rs62232870 was associated with an increased OR of 1.36 [1.25 – 1.48] ($p = 5.3 \cdot 10^{-13}$) in the combined discovery and replication samples. The pattern of association observed at this locus extends over several genes among which two, *TMEM43* and *SLC6A6*, are expressed in heart and have previously been suspected to be involved in human structural cardiac disorders. Rare pathogenic mutations in the *TMEM43*, transmembrane protein 43, have been reported in arrhythmogenic right ventricular cardiomyopathy(39–41) while a homozygous splice site deletion has been observed in *SLC6A6* in an idiopathic DCM patient(42). Taurine (TAU) is a highly concentrated amino-acide with cyto-protective action in numerous tissues, especially in contractile ones such as heart(43). Oral TAU supplementation is cardio-protective, while depletion associates with dilated cardiomyopathy in several mammalian species(44,45). Intracellular TAU concentration relies on its transmembrane transporter (TauT) expression and activity encoded by *SLC6A6*. Accordingly, mice KO for *slc6a6* present tissue TAU level depletion and dilated cardiomyopathy(46) and a recent publication revealed that long-term treatment of dystrophic mice with taurine could prevent late heart dysfunction (47). It is thus tempting to speculate that *SLC6A6* expression regulation in humans could influence cardiac function as well. Our finding of a genetic association of *SLC6A6* alleles with DCM is remarkable in this context. Moreover, based on LV transcriptomic data, we observed that *SLC6A6* expression was decreased in DCM patients compared to controls and that, for several SNPs in

LD with rs62232870-A lead-SNP, the allele associated with the rs62232870-A risk allele, showed a slight decrease in *SLC6A6* expression in heart atrial appendage (*i.e.* rs62231957 A allele is associated with the rs62232870-A risk allele and showed a decreased *SLC6A6* expression ($p=1.9 \times 10^{-5}$) (**Table 3** and **Supplementary Figure 11**).

As a whole, *in silico* annotation, chromatin interactions analysis showing specific interaction of the SNP LD block with *SLC6A6* regulatory elements and the well-reported role of taurine in cardiac function strongly suggest *SLC6A6* as the most likely gene influencing DCM phenotype at the 3p25.1 locus. The underlying pathway leading to heart failure remains to be fully studied in humans, but our results may suggest the potential for therapeutic perspective through taurine administration or up-regulation.

The second novel DCM locus maps to chr22q11.23, where the rs7284877 lead SNP, intronic to *SMARCB1*, is associated with DCM, the C-risk allele presenting an OR of 1.33 [1.22 – 1.46] ($p = 5.0 \times 10^{-10}$). Our fine-mapping revealed that, among the positional candidates, six demonstrated significant expression in heart and difference in LV gene expression between DCM and healthy heart (from the highest to the lowest: *CHCHD10*, *GSTT1*, *DDT*, *SMARCB1*, *CABIN1*, and *SLC2A11*) among which only *SMARCB1* (SWI/SNF related matrix-associated actin-dependent regulator of chromatin subfamily b member 1) was under the influence of the lead rs7284877 in LV. Interestingly, the lead SNP is in complete LD with *SMARCB1*-rs5760054 recently reported to associate with LV internal dimension in systole and fractional shortening in a multi-trait GWAS conducted in 162,255 Japanese individuals(48). Even though not regulated by rs7284877, two other highlighted genes were already implied in cardiovascular disorders and/or phenotypes. First, *GSTT1*, glutathione S-transferase theta 1, has been suggested to associate with various cardiovascular diseases(49,50). It is shown *via* RNA-seq

studies to be differentially expressed in heart depending on the pathological state: overexpression in male left ventricular hypertrophy (LVH) but downregulation in DCM heart compared to control(51); overexpression in DCM or non-failure vs. ischemic heart(52); Second, *CABIN1*, calcineurin binding protein 1, is a protein that binds to and inhibits calcineurin (CaN), a calcium-regulated phosphatase. CABIN1 is cleaved by calpain that is upregulated in heart failure LV. Calpain upregulation may increase cabin1 cleavage and thus lead to CaN overexpression in HF patients which can contribute to cardiac remodeling (53,54). Two other genes at this locus, *DERL3* and *MMP11*, were not included in our candidates because of their low cardiac expression but could nonetheless be interesting candidates. *DERL3*-rs5760061, in complete LD with rs7284877, associated with LV internal dimension and fractional shortening in the Japanese GWAS. Another SNP of this gene, rs6003909, in high LD ($r^2=0.8$) with rs7284877, also associated with LV geometric remodeling in a UK Biobank GWAS of LV image-derived phenotypes (55). We also found that another SNP, rs2186370, in complete LD with the lead SNP, is a mQTL strongly associated ($p=8.4 \cdot 10^{-71}$) with the methylation level of CpG cg25907215 lying in the 3'UTR of *DERL3*. *DERLIN3* (*DERL3*) plays a role in heart homeostasis maintenance (56,57) and its expression in skeletal muscle is under the control of DCM associated SNPs including the lead. *MMP11* has an expression consistently influenced by rs7284877. Interestingly, unlike the 10 other rs7284877 cis-regulated expressions, the eQTL activity on *MMP11* is quasi restricted to cardiac tissues ($p= 4 \cdot 10^{-20}$, $5.7 \cdot 10^{-15}$ and $7.4 \cdot 10^{-5}$ in heart left ventricle, heart atrial appendage, and cells-cultured fibroblast, respectively). *MMP11*, matrix metalloproteinase 11, encodes an enzyme implied in the regulation of extracellular matrix and in the development of myocardial fibrosis and ventricular remodeling(58,59) functions that could be related with DCM. Even though we did not select a striking candidate at this locus, *SMARCB1*, whose expression and methylation are directly

regulated by the lead SNP and associates with various cardiac phenotypes seems to be the stronger.

However, for both of these DNA loci with a regulatory function, it is also plausible that a single gene does not explain the whole functional activity detected(60). Given the strong bi-allelic activity of the enhancer regions in both loci and interaction shown in 4C data, multiple genes expressed in cardiomyocytes might be regulated in parallel to produce DCM phenotype.

Beyond the discovery of two novel DCM-associated loci, this GWAS investigation provided an innovative estimate of the heritability of the disease in European descent individuals, $h^2 = 31\% \pm 8\%$, a value consistent with that ($h^2 \sim 30\%$) recently reported in a population of African origin(12). However, the four independent lead SNPs (*BAG3*, *HSPB7*, chr3p25.1-*SLC6A6*, and chr22q11.23-*SMARCB1*) reaching genome-wide significance only contribute to 2% of the heritability suggesting the role of additional genetic factors or gene/gene and gene/environment interactions yet to be identified. Despite their modest contribution to the DCM heritability, these 4 SNPs may have clinical utility. Indeed, a GRS constructed on these 4 SNPs revealed that individuals with 8 risk alleles were at 30% increased risk of DCM and those with 1 risk allele at 19% reduced risk of DCM compared to individuals with 5 the risk alleles referral. This GRS, the first of its kind developed in the field of DCM, may have practical implications for better management of subjects at risk for DCM or systolic dysfunction, such as patients with drugs increasing the risk of myocardial dysfunction, or relatives in DCM families. Further clinical studies are warranted to validate its clinical utility.

Despite its innovative findings in the context of DCM, this study suffers from some limitations. First, we robustly identified two new DCM loci but were not able to fully demonstrate which culprit variant(s) and gene(s) are directly responsible for the observed

susceptibility to the disease. Further intensive molecular and cellular investigations are needed to fill this gap. Second, despite being the largest GWAS ever performed on DCM, with both a discovery and a replication phase, our GWAS may have been suboptimal in identifying common susceptibility DCM alleles due to the absence of perfectly matched healthy controls for the British and US populations. Therefore, we performed our discovery GWAS on combined individual data while handling any potential hidden population stratification through adjustment on genetically derived principal components. Nevertheless, the robust replication of 2 out of 3 genome-wide significant associations in two case-control studies of Dutch and German origins provides strong support for the validity of our general strategy. The replication of the reported genetic associations in non-European ancestry populations is now needed. Similarly, the in-depth interrogation of electronic health records database with GWAS data, such as UK biobank (<https://www.ukbiobank.ac.uk/>)(61) or the Million Veteran Program (<https://www.research.va.gov/mvp/>)(62), and DCM information, may increase the power to detect additional DCM associated loci.

In conclusion, we identified two new genetic loci associated with DCM. While *SLC6A6* clearly stands out as the most likely candidate at the chr3p25.1 locus, several plausible candidates *SMARCB1*, *DERL3*, and *MMP11* could be proposed at chr22q11.23 locus. A genetic risk score was built with a potential clinical application for the prediction of systolic heart failure. These findings add both on the understanding of the genetic architecture of DCM and on potential new players/pathways involved in the pathophysiology of systolic heart failure.

References

1. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. *Eur Heart J*. janv 2008;29(2):270-6.
2. Jefferies JL, Towbin JA. Dilated cardiomyopathy. *Lancet Lond Engl*. 27 févr 2010;375(9716):752-62.
3. Tayal U, Prasad S, Cook SA. Genetics and genomics of dilated cardiomyopathy and systolic heart failure. *Genome Med*. 22 2017;9(1):20.
4. Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Böhm M, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. *Eur Heart J*. 14 2016;37(23):1850-8.
5. McNally EM, Golbus JR, Puckelwartz MJ. Genetic mutations and mechanisms in dilated cardiomyopathy. *J Clin Invest*. janv 2013;123(1):19-26.
6. Harakalova M, Kummeling G, Sammani A, Linschoten M, Baas AF, van der Smagt J, et al. A systematic analysis of genetic dilated cardiomyopathy reveals numerous ubiquitously expressed and muscle-specific genes. *Eur J Heart Fail*. mai 2015;17(5):484-93.
7. Stark K, Esslinger UB, Reinhard W, Petrov G, Winkler T, Komajda M, et al. Genetic association study identifies HSPB7 as a risk gene for idiopathic dilated cardiomyopathy. *PLoS Genet*. 21 oct 2010;6(10):e1001167.
8. Cappola TP, Li M, He J, Ky B, Gilmore J, Qu L, et al. Common variants in HSPB7 and FRMD4B associated with advanced heart failure. *Circ Cardiovasc Genet*. avr 2010;3(2):147-54.
9. Villard E, Perret C, Gary F, Proust C, Dilanian G, Hengstenberg C, et al. A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. *Eur Heart J*. mai 2011;32(9):1065-76.
10. Meder B, Rühle F, Weis T, Homuth G, Keller A, Franke J, et al. A genome-wide association study identifies 6p21 as novel risk locus for dilated cardiomyopathy. *Eur Heart J*. avr 2014;35(16):1069-77.
11. Esslinger U, Garnier S, Korniat A, Proust C, Kararigas G, Müller-Nurasyid M, et al. Exome-wide association study reveals novel susceptibility genes to sporadic dilated cardiomyopathy. *PLoS One*. 2017;12(3):e0172995.
12. Xu H, Dorn GW, Shetty A, Parihar A, Dave T, Robinson SW, et al. A Genome-Wide Association Study of Idiopathic Dilated Cardiomyopathy in African Americans. *J Pers Med*. 26 2018;8(1).
13. Aragam KG, Chaffin M, Levinson RT, McDermott G, Choi S-H, Shoemaker MB, et al. Phenotypic Refinement of Heart Failure in a National Biobank Facilitates Genetic Discovery. *Circulation*. 11 nov 2018;

14. Norton N, Li D, Rieder MJ, Siegfried JD, Rampersaud E, Züchner S, et al. Genome-wide studies of copy number variation and exome sequencing identify rare variants in BAG3 as a cause of dilated cardiomyopathy. *Am J Hum Genet.* 11 mars 2011;88(3):273-82.
15. Henry WL, Gardin JM, Ware JH. Echocardiographic measurements in normal subjects from infancy to old age. *Circulation.* nov 1980;62(5):1054-61.
16. Mestroni L, Maisch B, McKenna WJ, Schwartz K, Charron P, Rocco C, et al. Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. *Eur Heart J.* janv 1999;20(2):93-102.
17. Sammani A, Jansen M, Linschoten M, Bagheri A, de Jonge N, Kirkels H, et al. UNRAVEL: big data analytics research data platform to improve care of patients with cardiomyopathies using routine electronic health records and standardised biobanking. *Neth Heart J Mon J Neth Soc Cardiol Neth Heart Found.* 27 mai 2019;
18. Angelow A, Schmidt M, Hoffmann W. Towards risk factor assessment in inflammatory dilated cardiomyopathy: the SFB/TR 19 study. *Eur J Cardiovasc Prev Rehabil Off J Eur Soc Cardiol Work Groups Epidemiol Prev Card Rehabil Exerc Physiol.* oct 2007;14(5):686-93.
19. Völzke H, Alte D, Schmidt CO, Radke D, Lorbeer R, Friedrich N, et al. Cohort profile: the study of health in Pomerania. *Int J Epidemiol.* avr 2011;40(2):294-307.
20. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. *Genet Epidemiol.* déc 2010;34(8):816-34.
21. Li Y, Willer C, Sanna S, Abecasis G. Genotype imputation. *Annu Rev Genomics Hum Genet.* 2009;10:387-406.
22. Tregouet DA, Garelle V. A new JAVA interface implementation of THESIAS: testing haplotype effects in association studies. *Bioinforma Oxf Engl.* 15 avr 2007;23(8):1038-9.
23. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinforma Oxf Engl.* 1 sept 2010;26(17):2190-1.
24. Zheng J, Erzurumluoglu AM, Elsworth BL, Kemp JP, Howe L, Haycock PC, et al. LD Hub: a centralized database and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis. *Bioinforma Oxf Engl.* 15 2017;33(2):272-9.
25. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, et al. The human genome browser at UCSC. *Genome Res.* juin 2002;12(6):996-1006.
26. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. *Nature.* 6 sept 2012;489(7414):57-74.
27. Saha A, Kim Y, Gewirtz ADH, Jo B, Gao C, McDowell IC, et al. Co-expression networks reveal the tissue-specific regulation of transcription and splicing. *Genome Res.* 2017;27(11):1843-58.
28. Leung D, Jung I, Rajagopal N, Schmitt A, Selvaraj S, Lee AY, et al. Integrative analysis of haplotype-resolved epigenomes across human tissues. *Nature.* 19 févr 2015;518(7539):350-4.

29. Lesurf R, Cotto KC, Wang G, Griffith M, Kasaian K, Jones SJM, et al. ORegAnno 3.0: a community-driven resource for curated regulatory annotation. *Nucleic Acids Res.* 4 janv 2016;44(D1):D126-132.
30. Blanchette M, Kent WJ, Riemer C, Elnitski L, Smit AFA, Roskin KM, et al. Aligning multiple genomic sequences with the threaded blockset aligner. *Genome Res.* avr 2004;14(4):708-15.
31. Dixon JR, Gorkin DU, Ren B. Chromatin Domains: The Unit of Chromosome Organization. *Mol Cell.* 02 2016;62(5):668-80.
32. Montefiori LE, Sobreira DR, Sakabe NJ, Aneas I, Joslin AC, Hansen GT, et al. A promoter interaction map for cardiovascular disease genetics. *eLife.* 10 2018;7.
33. Heinig M, Adriaens ME, Schafer S, van Deutekom HWM, Lodder EM, Ware JS, et al. Natural genetic variation of the cardiac transcriptome in non-diseased donors and patients with dilated cardiomyopathy. *Genome Biol.* 14 2017;18(1):170.
34. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res.* sept 2010;38(16):e164.
35. Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, et al. Annotation of functional variation in personal genomes using RegulomeDB. *Genome Res.* sept 2012;22(9):1790-7.
36. Smedley D, Schubach M, Jacobsen JOB, Köhler S, Zemojtel T, Spielmann M, et al. A Whole-Genome Analysis Framework for Effective Identification of Pathogenic Regulatory Variants in Mendelian Disease. *Am J Hum Genet.* 01 2016;99(3):595-606.
37. Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. *Nat Genet.* mars 2014;46(3):310-5.
38. Lemire M, Zaidi SHE, Ban M, Ge B, Aïssi D, Germain M, et al. Long-range epigenetic regulation is conferred by genetic variation located at thousands of independent loci. *Nat Commun.* 26 févr 2015;6:6326.
39. Honda T, Kanai Y, Ohno S, Ando H, Honda M, Niwano S, et al. Fetal arrhythmogenic right ventricular cardiomyopathy with double mutations in TMEM43. *Pediatr Int Off J Jpn Pediatr Soc.* mai 2016;58(5):409-11.
40. Siragam V, Cui X, Masse S, Ackerley C, Aafaqi S, Strandberg L, et al. TMEM43 mutation p.S358L alters intercalated disc protein expression and reduces conduction velocity in arrhythmogenic right ventricular cardiomyopathy. *PLoS One.* 2014;9(10):e109128.
41. Bao J, Wang J, Yao Y, Wang Y, Fan X, Sun K, et al. Correlation of ventricular arrhythmias with genotype in arrhythmogenic right ventricular cardiomyopathy. *Circ Cardiovasc Genet.* déc 2013;6(6):552-6.
42. Shakeel M, Irfan M, Khan IA. Rare genetic mutations in Pakistani patients with dilated cardiomyopathy. *Gene.* 5 oct 2018;673:134-9.
43. Xu Y-J, Arneja AS, Tappia PS, Dhalla NS. The potential health benefits of taurine in cardiovascular disease. *Exp Clin Cardiol.* 2008;13(2):57-65.

44. Pion PD, Kittleson MD, Rogers QR, Morris JG. Myocardial failure in cats associated with low plasma taurine: a reversible cardiomyopathy. *Science*. 14 août 1987;237(4816):764-8.
45. Kaplan JL, Stern JA, Fascetti AJ, Larsen JA, Skolnik H, Peddle GD, et al. Taurine deficiency and dilated cardiomyopathy in golden retrievers fed commercial diets. *PloS One*. 2018;13(12):e0209112.
46. Ito T, Oishi S, Takai M, Kimura Y, Uozumi Y, Fujio Y, et al. Cardiac and skeletal muscle abnormality in taurine transporter-knockout mice. *J Biomed Sci*. 24 août 2010;17 Suppl 1:S20.
47. Mele A, Mantuano P, De Bellis M, Rana F, Sanarica F, Conte E, et al. A long-term treatment with taurine prevents cardiac dysfunction in mdx mice. *Transl Res J Lab Clin Med*. 2019;204:82-99.
48. Kanai M, Akiyama M, Takahashi A, Matoba N, Momozawa Y, Ikeda M, et al. Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases. *Nat Genet*. mars 2018;50(3):390-400.
49. Song Y, Shan Z, Luo C, Kang C, Yang Y, He P, et al. Glutathione S-Transferase T1 (GSTT1) Null Polymorphism, Smoking, and Their Interaction in Coronary Heart Disease: A Comprehensive Meta-Analysis. *Heart Lung Circ*. avr 2017;26(4):362-70.
50. García-González I, López-Díaz RI, Canché-Pech JR, Solís-Cárdenas A de J, Flores-Ocampo JA, Mendoza-Alcocer R, et al. Epistasis analysis of metabolic genes polymorphisms associated with ischemic heart disease in Yucatan. *Clin E Investig En Arterioscler Publicacion Of Soc Espanola Arterioscler*. juin 2018;30(3):102-11.
51. Newman MS, Nguyen T, Watson MJ, Hull RW, Yu H-G. Transcriptome profiling reveals novel BMI- and sex-specific gene expression signatures for human cardiac hypertrophy. *Physiol Genomics*. 1 juill 2017;49(7):355-67.
52. Liu Y, Morley M, Brandimarto J, Hannenhalli S, Hu Y, Ashley EA, et al. RNA-Seq identifies novel myocardial gene expression signatures of heart failure. *Genomics*. févr 2015;105(2):83-9.
53. Yang D, Ma S, Tan Y, Li D, Tang B, Zhang X, et al. Increased expression of calpain and elevated activity of calcineurin in the myocardium of patients with congestive heart failure. *Int J Mol Med*. juill 2010;26(1):159-64.
54. Yang Y, Zhu W, Zhou X, Zhang X, Zhu Z. [Calpain involved in signal transduction of myocardial remodeling in patients with congestive heart failure]. *Zhonghua Xin Xue Guan Bing Za Zhi*. mars 2005;33(3):247-50.
55. Aung N, Vargas JD, Yang C, Cabrera CP, Warren HR, Fung K, et al. Genome-Wide Analysis of Left Ventricular Image-Derived Phenotypes Identifies Fourteen Loci Associated With Cardiac Morphogenesis and Heart Failure Development. *Circulation*. 15 oct 2019;140(16):1318-30.
56. Belmont PJ, Chen WJ, San Pedro MN, Thuerlauf DJ, Gellings Lowe N, Gude N, et al. Roles for endoplasmic reticulum-associated degradation and the novel endoplasmic reticulum stress response gene Derlin-3 in the ischemic heart. *Circ Res*. 5 févr 2010;106(2):307-16.
57. Glembotski CC. Roles for ATF6 and the sarco/endoplasmic reticulum protein quality control system in the heart. *J Mol Cell Cardiol*. juin 2014;71:11-5.

58. Li YY, McTiernan CF, Feldman AM. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. *Cardiovasc Res.* mai 2000;46(2):214-24.
59. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? *Circ Res.* 3 août 2001;89(3):201-10.
60. Haitjema S, Meddens CA, van der Laan SW, Kofink D, Harakalova M, Tragante V, et al. Additional Candidate Genes for Human Atherosclerotic Disease Identified Through Annotation Based on Chromatin Organization. *Circ Cardiovasc Genet.* avr 2017;10(2).
61. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med.* mars 2015;12(3):e1001779.
62. Gaziano JM, Concato J, Brophy M, Fiore L, Pyarajan S, Breeling J, et al. Million Veteran Program: A mega-biobank to study genetic influences on health and disease. *J Clin Epidemiol.* févr 2016;70:214-23.

Acknowledgment

Funding

This work was supported by grants from the GENMED Laboratory of Excellence on Medical Genomics (ANR-10-LABX-0013), DETECTIN-HF project (ERA-CVD framework), Assistance Publique-Hôpitaux de Paris (PHRC programme hospitalier de recherche Clinique, AOM04141), Délégation à la recherche clinique AP-HP (EMUL and PHRC n°AOM95082), the 'Fondation LEDUCQ' (Eurogene Heart Failure network; 11CVD 01), the PROMEX charitable foundation, the Société Française de Cardiologie/Fédération Française de Cardiologie.

The SFB-TR19 registry was supported by the Deutsche Forschungsgemeinschaft (DFG). The Study of Health in Pomerania (SHIP) is part of the Community Medicine Research net of the University of Greifswald, Germany, funded by the Federal Ministry of Education and Research (Grants 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs and the Social Ministry of the Federal State of Mecklenburg-West Pomerania. This work was also funded in part by grants from the German Center for Cardiovascular Research (DZHK).

The KORA study was initiated and financed by the Helmholtz Zentrum München – German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. Furthermore, KORA research was supported within the Munich Center of Health Sciences (MC-Health), Ludwig-Maximilians-Universität, as part of LMUinnovativ

Benjamin Meder is supported by grants from the Deutsches Zentrum für Herz-Kreislauf-Forschung (German Center for Cardiovascular Research, DZHK), the German Ministry of Education and Research (CaRNation, FKZ 031L0075B), Informatics for Life (Klaus Tschira

Foundation), the Deutsche Forschungsgemeinschaft (DFG) and by an excellence fellowship of the Else Kröner Fresenius Foundation.

Folkert Asselbergs is supported by UCL Hospitals NIHR Biomedical Research Centre and Magdalena Harakalova by the NWO VENI grant (no. 016.176.136).

Tables and Figures

Figure 1. Manhattan plot summarizing the discovery GWAS results

Figure 2. Barplot of the unweighted (A) and weighted (B) scores

Figure 3. Maps of DNA regulatory features and overview of chromosome 3 (A.) and 22 (B.) associated regions

Figure 4. TAD domains delimitation at chromosome 3 (A.) and 22 (B.) loci

Table 1. Discovery GWAS results, replications, and combined analysis results

Table 2. Unweighted (A) and weighted (B) scores

Table 3. Lead SNPs (or proxies) eQTLs effect on candidate genes at chromosome 3 and 22 loci

Table 4. SNP annotation

Supplementary Tables and Figures

Supplementary Figure 1. QQplot summarizing the discovery GWAS results

Supplementary Figure 2 to 6. Regional-association-plot at chromosome 1, 3, 10, 16 and 22

Supplementary Figure 7-8. Manhattan and QQ summarizing the discovery GWAS conditional-analysis results

Supplementary Figure 9. Barplot of the weighted scores grouped by quintile

Supplementary Figure 10. Violin-plot showing the regulation of *SMARCB1* (a) and *MMP11* (b) expression by rs7284877 lead SNP

Supplementary Figure 11. Violin-plot showing the regulation of *SLC6A* by rs62231950

Supplementary Table 1. Genotyping methods and quality controls

Supplementary Table 2. Haplotypic-association signal at chromosome 3 locus

Supplementary Table 3. Unweighted (A) and weighted (B) scores replications

Supplementary Table 4. SNPs' LD block at chromosome 3 and 22 loci

Supplementary Table 5. List of the gene at chromosome 3 and 22 loci

Supplementary Table 6. 4C interaction at chromosome 3 locus

Supplementary Table 7. Gene Expression level at chromosome 3 and 22 loci

Supplementary Table 8. 4C interaction at chromosome 22 locus

Supplementary Table 9. 4C-seq primers

Figure 1. Manhattan plot summarizing the DCM GWAS results

Figure2A. Unweighted Genetic Risk Score for the 6,980 individuals of the discovery cohort and associated OR taking score 5 (presence of 5 risk alleles) as reference

Figure2B. Weighted* Genetic Risk Score for the 6,980 individuals of the discovery cohort and associated OR taking the score 1.6 as reference

*Score of each SNP weighted by the beta value of this SNP in the sub meta-analysis of the two replication cohorts

Figure 3. Maps of regulatory DNA features of chromosome 3p25.1 (A) and 22q11.23 (B) associated regions. The associated region is located in a gene desert with long non-coding RNA (lncRNA) sequences for chr3p25.1 [chr3:14,257,356-14,307,016] but covered *MMP11*, *SMARCB1*, *DERL3* and lncRNA at chr22q11.23 [chr22:24,110,180-24,182,174]. All SNPs with association p-value $< 5 \cdot 10^{-8}$ and/or in LD ($r^2 \geq 0.7$) with the lead SNPs (rs62232870 in red; rs4684185 in dark blue; rs7284877 in dark green) are indicated. The SNPs in LD with the lead SNPs are colored orange, light blue and light green, respectively. Features associated with regulatory sequence elements are aligned under the SNPs track (Associated SNPs track) and show that the loci contain enhancer signature according to H3K27ac, H3K4me1 and H3K4me3 ChIP-seq signals prediction for left ventricle enhancers by Leung et al²⁵, positive OregAnno regulatory element score²⁶, conservation between vertebrates species²⁷, DNaseI hypersensitivity and ChIP-seq signal for chromatin interacting proteins linked to transcription activity. Vertical blue lines highlight SNPs with Regulome (<http://www.regulomedb.org/>)³³ prediction score below 4 indicating significant potential for being regulatory variants (see **Table 4** for more details)

B.

Figure 4. Positional candidate genes located in TAD domains at chromosome 3p25.1 (left) and 22q11.23 (right) loci. To delimitate the chromatin Topology Associated Domains (TADs) where genes are accessible to intra-TAD regulatory elements such as enhancers⁽²⁸⁾, we first looked for publicly available Left Ventricle Topology Associating Domain²⁵ (track b). TAD boundaries were comforted by the results of in-house Circular Chromatin Conformation Capture (4C)-Sequencing data produced on a iPSC-derived cardiomyocyte line from a donor (fully described in Supplemental Material iPSC reprogramming paragraph); 4C baits localization is schematized as a vertical black bar (track g). The p-values for interaction below 10^{-8} are shown as a blue scale colored bar given below. We then looked at the preferential chromatin interactions measured *via* PChI-C (Promoter Chromatin Hi-C)²⁹ on iPS derived cardiomyocytes (gene promoters predicted from GenHancer (<https://www.genecards.org/>)) that revealed preferential contact inside TADs as shown by the red curves (track f) and defined the intra-TAD candidate gene list (track c) prone to be regulated in *cis* by associated regions (blue highlight, track a. The color code for the SNP is identical to that of close figure 3). Specific DNA interactions are joining associated regions with histone enhancer marks (H3K27ac; H3K4me1, track d and e respectively

Table 1. Main association findings of the DCM GWAS results

		rs62232870	rs4684185	rs148248535*	rs7284877
	Chromosome	3	3	16	22
	Position (GRCh37.p13)	14257709	14272914	2183449	24155111
	Locus	LSM3	LSM3	PKD1	SMARCB1
	Risk Allele	A	C	T	C
Discovery					
	RAF ^a	0.23	0.70	0.82	0.81
	Imputation r^2	0.96	0.99	0.89	0.99
	Allelic OR	1.36	1.28	1.35	1.32
	[95% CI]	[1.24-1.49]	[1.17-1.40]	[1.21-1.50]	[1.20-1.46]
	P	8.7×10^{-11}	8.4×10^{-9}	3.0×10^{-8}	3.3×10^{-8}
Replication					
Dutch study	RAF ^a	0.22	0.70	0.84	0.79
	Imputation r^2	0.95	0.99	0.92	0.99
	Allelic OR	1.54	1.45	1.21	1.75
	[95% CI]	[1.00-2.35]	[1.03-2.04]	[0.77-1.90]	[1.44-2.68]
	p^b	0.024	0.017	0.199	4×10^{-3}
German study	RAF ^a	0.22	0.71	0.84	0.82
	Imputation r^2	NA	NA	NA	NA
	Allelic OR	1.36	1.19	1.13	1.26
	[95% CI]	[1.08-1.71]	[0.96-1.46]	[0.88-1.46]	[0.99-1.61]
	p^b	5.6×10^{-3}	0.046	0.172	0.031
Sub meta-analysis	Allelic OR	1.38	1.26	1.16	1.39
	[95% CI]	[1.13-1.69]	[1.05-1.51]	[0.91-1.47]	[1.12-1.72]
	P^c	7.7×10^{-4}	6×10^{-3}	0.11	1.4×10^{-3}
	Q^d	0.30	0.87	0.05	0.85
	I^2^e	0	0	0	0
Sub meta-analysis	P_{het}^f	0.58	0.35	0.81	0.36
Combined Discovery + Replication					
	Allelic OR	1.36	1.27	1.31	1.33
	[95% CI]	[1.25-1.48]	[1.18-1.37]	[1.19-1.45]	[1.22-1.46]
	P^c	5.3×10^{-13}	4.8×10^{-10}	3.4×10^{-8}	5.0×10^{-10}
	Q^d	0.33	0.89	1.33	1.82
	I^2^e	0	0	0	0
	P_{het}^f	0.85	0.64	0.51	0.40

*For German replication, association analysis was done with rs35786 serving as a proxy for rs148248535 ($r^2=0.97$)

^a Risk Allele Frequency

^b One-sided p-value

^c Two-sided combined p-value derived from a fixed effect meta-analysis of the discovery and replication results.

^d Cochran's Q estimates heterogeneity across studies

^e I^2 index describes the magnitude of the heterogeneity

^f p-value of the heterogeneity test across studies

Table 2A: Unweighted Genetic Score for the 6,980 individuals of the discovery cohort and associated OR taking the score 5 as reference.

	Discovery Cohort		
Risk allele number	Size	p-value	Odds Ratio [$\pm$ CI]
1	22	0.012	0.79 [0.66-0.95]
2	121	$3.20 \cdot 10^{-05}$	0.85 [0.79-0.92]
3	594	$4.98 \cdot 10^{-05}$	0.92 [0.89-0.96]
4	1638	$1.56 \cdot 10^{-05}$	0.94 [0.91-0.97]
5	2262	Reference	Reference
6	1682	$6.07 \cdot 10^{-06}$	1.07 [1.04-1.10]
7	598	$8.00 \cdot 10^{-10}$	1.13 [1.09-1.18]
8	63	$2.05 \cdot 10^{-05}$	1.27 [1.14-1.42]

Table 2B: Weighted Genetic Score for the 6,980 individuals of the discovery cohort and associated OR taking the score 1.6 as reference.

Weighing was realized taking the sub-meta-analysis (two replication cohorts) beta value

	Discovery Cohort		
Weighted Score	Size	p-value	Odds Ratio [$\pm$ CI]
0,4	22	0.024	0.81 [0.67-0.97]
0,8	121	$7.12 \cdot 10^{-04}$	0.87 [0.80-0.94]
1,2	793	$5.56 \cdot 10^{-04}$	0.94 [0.91-0.97]
1,6	3694	Reference	Reference
2	1689	$1.67 \cdot 10^{-11}$	1.09 [1.06-1.12]
2,4	598	$3.48 \cdot 10^{-14}$	1.16 [1.12-1.20]
2,8	63	$2.82 \cdot 10^{-06}$	1.30 [1.16-1.45]

Table 3: Lead SNPs (or proxies) eQTLs effect, according to GTEx portal, on candidate genes at chromosome 3p25.1 and 22q11.23 loci * Lead SNP at chr3p25.1 (rs62232870) and chr22q11.23 (rs7284877) or proxies whose r^2 with the lead, >0.6 , is given into brackets

rsID*	eSNP localization	Chr	Regulated Gene	Chr	eSNP p-value	Tissue	p-value GWAS
rs7612736 (r^2 : 0.71)	Downstream <i>LSM3</i>	3	<i>SLC6A6</i>	3	$5.8 \cdot 10^{-05}$	Heart Atrial Appendage	$1.6 \cdot 10^{-09}$
rs17305149 (r^2 : 0.71)	Downstream <i>LSM3</i>	3	<i>SLC6A6</i>	3	$5.8 \cdot 10^{-05}$	Heart Atrial Appendage	$2.6 \cdot 10^{-09}$
rs62231950 (r^2 : 0.71)	Downstream <i>LSM3</i>	3	<i>SLC6A6</i>	3	$5.5 \cdot 10^{-05}$	Heart Atrial Appendage	$3.1 \cdot 10^{-09}$
rs4685090 (r^2 : 0.71)	Downstream <i>LSM3</i>	3	<i>SLC6A6</i>	3	$3.4 \cdot 10^{-05}$	Heart Atrial Appendage	$2.4 \cdot 10^{-09}$
rs113608926 (r^2 : 0.69)	Downstream <i>LSM3</i>	3	<i>SLC6A6</i>	3	$8.5 \cdot 10^{-05}$	Heart Atrial Appendage	$3.1 \cdot 10^{-08}$
rs62231954 (r^2 : 0.69)	Downstream <i>LSM3</i>	3	<i>SLC6A6</i>	3	$8.5 \cdot 10^{-05}$	Heart Atrial Appendage	$3.4 \cdot 10^{-08}$
rs62231956 (r^2 : 0.69)	Downstream <i>LSM3</i>	3	<i>SLC6A6</i>	3	$8.5 \cdot 10^{-05}$	Heart Atrial Appendage	$3.7 \cdot 10^{-08}$
rs62231957 (r^2 : 0.69)	Downstream <i>LSM3</i>	3	<i>SLC6A6</i>	3	$1.9 \cdot 10^{-05}$	Heart Atrial Appendage	$3.8 \cdot 10^{-08}$
rs62231958 (r^2 : 0.69)	Downstream <i>LSM3</i>	3	<i>SLC6A6</i>	3	$4.9 \cdot 10^{-05}$	Heart Atrial Appendage	$4.5 \cdot 10^{-08}$
rs62231959 (r^2 : 0.69)	Downstream <i>LSM3</i>	3	<i>SLC6A6</i>	3	$4.9 \cdot 10^{-05}$	Heart Atrial Appendage	$4.5 \cdot 10^{-08}$
rs55824951 (r^2 : 0.69)	Downstream <i>LSM3</i>	3	<i>SLC6A6</i>	3	$4.9 \cdot 10^{-05}$	Heart Atrial Appendage	$4.8 \cdot 10^{-08}$
rs7284877	<i>SMARCB1</i>	22	<i>SMARCB1</i>	22	$1.5 \cdot 10^{-13}$	Heart Atrial Appendage	$3.3 \cdot 10^{-08}$
rs7284877	<i>SMARCB1</i>	22	<i>SMARCB1</i>	22	$2.8 \cdot 10^{-12}$	Heart Left Ventricle	$3.3 \cdot 10^{-08}$
rs7284877	<i>SMARCB1</i>	22	<i>MMP11</i>	22	$2.8 \cdot 10^{-13}$	Heart Left Ventricle	$3.3 \cdot 10^{-08}$
rs7284877	<i>SMARCB1</i>	22	<i>MMP11</i>	22	$4.3 \cdot 10^{-8}$	Heart Atrial Appendage	$3.3 \cdot 10^{-08}$
rs7284877	<i>SMARCB1</i>	22	<i>SMARCB1</i>	22	$4.9 \cdot 10^{-13}$	Skeletal muscle	$3.3 \cdot 10^{-08}$
rs7284877	<i>SMARCB1</i>	22	<i>VPREB3</i>	22	$1.4 \cdot 10^{-12}$	Skeletal muscle	$3.3 \cdot 10^{-08}$
rs7284877	<i>SMARCB1</i>	22	<i>DERL3</i>	22	$3.5 \cdot 10^{-08}$	Skeletal muscle	$3.3 \cdot 10^{-08}$
rs9608201 (r^2 : 1)	<i>SMARCB1</i>	22	<i>MMP11</i>	22	$2.5 \cdot 10^{-24}$	Heart Left Ventricle	$3.8 \cdot 10^{-08}$
rs9608201 (r^2 : 1)	<i>SMARCB1</i>	22	<i>MMP11</i>	22	$3.3 \cdot 10^{-16}$	Heart Atrial Appendage	$3.8 \cdot 10^{-08}$
rs9608201 (r^2 : 1)	<i>SMARCB1</i>	22	<i>SMARCB1</i>	22	$7.3 \cdot 10^{-22}$	Heart Left Ventricle	$3.8 \cdot 10^{-08}$
rs9608201 (r^2 : 1)	<i>SMARCB1</i>	22	<i>SMARCB1</i>	22	$3.3 \cdot 10^{-16}$	Heart Atrial Appendage	$3.8 \cdot 10^{-08}$
rs9608201 (r^2 : 1)	<i>SMARCB1</i>	22	<i>SMARCB1</i>	22	$3.0 \cdot 10^{-18}$	Skeletal muscle	$3.8 \cdot 10^{-08}$

rs9608201 (r ² : 1)	SMARCB1	22	VPREB3	22	1.9 10 ⁻⁸	Heart Left Ventricle	3.8 10 ⁻⁰⁸
rs9608201 (r ² : 1)	SMARCB1	22	VPREB3	22	3.7 10 ⁻¹⁸	Skeletal muscle	3.8 10 ⁻⁰⁸
rs9608201 (r ² : 1)	SMARCB1	22	DERL3	22	1.2 10 ⁻⁶	Skeletal muscle	3.8 10 ⁻⁰⁸
rs2186370 (r ² : 1)	SMARCB1	22	MMP11	22	2.5 10 ⁻²⁴	Heart Left Ventricle	3.8 10 ⁻⁰⁸
rs2186370 (r ² : 1)	SMARCB1	22	MMP11	22	3.3 10 ⁻¹⁶	Heart Atrial Appendage	3.8 10 ⁻⁰⁸
rs2186370 (r ² : 1)	SMARCB1	22	SMARCB1	22	7.3 10 ⁻²²	Heart Left Ventricle	3.8 10 ⁻⁰⁸
rs2186370 (r ² : 1)	SMARCB1	22	SMARCB1	22	7.5 10 ⁻¹⁷	Heart Atrial Appendage	3.8 10 ⁻⁰⁸
rs2186370 (r ² : 1)	SMARCB1	22	SMARCB1	22	3.0 10 ⁻¹⁸	Skeletal muscle	3.8 10 ⁻⁰⁸
rs2186370 (r ² : 1)	SMARCB1	22	VPREB3	22	1.9 10 ⁻⁸	Heart Left Ventricle	3.8 10 ⁻⁰⁸
rs2186370 (r ² : 1)	SMARCB1	22	VPREB3	22	3.7 10 ⁻¹⁸	Skeletal muscle	3.8 10 ⁻⁰⁸
rs2186370 (r ² : 1)	SMARCB1	22	DERL3	22	8.1 10 ⁻⁵	Skeletal muscle	3.8 10 ⁻⁰⁸
rs5760054 (r ² : 1)	SMARCB1	22	MMP11	22	2.5 10 ⁻²⁴	Heart Left Ventricle	3.9 10 ⁻⁰⁸
rs5760054 (r ² : 1)	SMARCB1	22	MMP11	22	3.3 10 ⁻¹⁶	Heart Atrial Appendage	3.9 10 ⁻⁰⁸
rs5760054 (r ² : 1)	SMARCB1	22	SMARCB1	22	7.3 10 ⁻²²	Heart Left Ventricle	3.9 10 ⁻⁰⁸
rs5760054 (r ² : 1)	SMARCB1	22	SMARCB1	22	7.5 10 ⁻¹⁷	Heart Atrial Appendage	3.9 10 ⁻⁰⁸
rs5760054 (r ² : 1)	SMARCB1	22	SMARCB1	22	3.0 10 ⁻¹⁸	Skeletal muscle	3.9 10 ⁻⁰⁸
rs5760054 (r ² : 1)	SMARCB1	22	VPREB3	22	1.9 10 ⁻⁸	Heart Left Ventricle	3.9 10 ⁻⁰⁸
rs5760054 (r ² : 1)	SMARCB1	22	VPREB3	22	3.7 10 ⁻¹⁸	Skeletal muscle	3.9 10 ⁻⁰⁸
rs5760054 (r ² : 1)	SMARCB1	22	DERL3	22	1.2 10 ⁻⁶	Skeletal muscle	3.9 10 ⁻⁰⁸
rs2070458 (r ² : 1)	SMARCB1	22	MMP11	22	2.5 10 ⁻²⁴	Heart Left Ventricle	3.9 10 ⁻⁰⁸
rs2070458 (r ² : 1)	SMARCB1	22	MMP11	22	3.3 10 ⁻¹⁶	Heart Atrial Appendage	3.9 10 ⁻⁰⁸
rs2070458 (r ² : 1)	SMARCB1	22	SMARCB1	22	7.3 10 ⁻²²	Heart Left Ventricle	3.9 10 ⁻⁰⁸
rs2070458 (r ² : 1)	SMARCB1	22	SMARCB1	22	7.5 10 ⁻¹⁷	Heart Atrial Appendage	3.9 10 ⁻⁰⁸
rs2070458 (r ² : 1)	SMARCB1	22	SMARCB1	22	3.0 10 ⁻¹⁸	Skeletal muscle	3.9 10 ⁻⁰⁸
rs2070458 (r ² : 1)	SMARCB1	22	VPREB3	22	1.9 10 ⁻⁸	Heart Left Ventricle	3.9 10 ⁻⁰⁸
rs2070458 (r ² : 1)	SMARCB1	22	VPREB3	22	3.7 10 ⁻¹⁸	Skeletal muscle	3.9 10 ⁻⁰⁸

rs2070458 (r ² : 1)	SMARCB1	22	DERL3	22	1.2 10 ⁻⁶	Skeletal muscle	3.9 10 ⁻⁰⁸
rs2267032 (r ² : 1)	SMARCB1	22	MMP11	22	4 10 ⁻²⁰	Heart Left Ventricle	4.2 10 ⁻⁰⁸
rs2267032 (r ² : 1)	SMARCB1	22	MMP11	22	5.7 10 ⁻¹⁵	Heart Atrial Appendage	4.2 10 ⁻⁰⁸
rs2267032 (r ² : 1)	SMARCB1	22	SMARCB1	22	7.3 10 ⁻²⁰	Heart Left Ventricle	4.2 10 ⁻⁰⁸
rs2267032 (r ² : 1)	SMARCB1	22	SMARCB1	22	8.7 10 ⁻¹⁶	Heart Atrial Appendage	4.2 10 ⁻⁰⁸
rs2267032 (r ² : 1)	SMARCB1	22	SMARCB1	22	1.3 10 ⁻¹⁶	Skeletal muscle	4.2 10 ⁻⁰⁸
rs2267032 (r ² : 1)	SMARCB1	22	VPREB3	22	2.5 10 ⁻⁹	Heart Left Ventricle	4.2 10 ⁻⁰⁸
rs2267032 (r ² : 1)	SMARCB1	22	VPREB3	22	1.0 10 ⁻¹⁷	Skeletal muscle	4.2 10 ⁻⁰⁸
rs2267032 (r ² : 1)	SMARCB1	22	DERL3	22	6.5 10 ⁻⁶	Skeletal muscle	4.2 10 ⁻⁰⁸
rs5760032 (r ² : 1)	SMARCB1	22	MMP11	22	4 10 ⁻²⁰	Heart Left Ventricle	4.4 10 ⁻⁰⁸
rs5760032 (r ² : 1)	SMARCB1	22	MMP11	22	5.7 10 ⁻¹⁵	Heart Atrial Appendage	4.4 10 ⁻⁰⁸
rs5760032 (r ² : 1)	SMARCB1	22	SMARCB1	22	7.3 10 ⁻²⁰	Heart Left Ventricle	4.4 10 ⁻⁰⁸
rs5760032 (r ² : 1)	SMARCB1	22	SMARCB1	22	8.7 10 ⁻¹⁶	Heart Atrial Appendage	4.4 10 ⁻⁰⁸
rs5760032 (r ² : 1)	SMARCB1	22	SMARCB1	22	7.8 10 ⁻¹⁷	Skeletal muscle	4.4 10 ⁻⁰⁸
rs5760032 (r ² : 1)	SMARCB1	22	VPREB3	22	2.5 10 ⁻⁹	Heart Left Ventricle	4.4 10 ⁻⁰⁸
rs5760032 (r ² : 1)	SMARCB1	22	VPREB3	22	1.1 10 ⁻¹⁷	Skeletal muscle	4.4 10 ⁻⁰⁸
rs5760032 (r ² : 1)	SMARCB1	22	DERL3	22	6.2 10 ⁻⁶	Skeletal muscle	4.4 10 ⁻⁰⁸
rs5760061 (r ² : 1)	SMARCB1	22	MMP11	22	2.5 10 ⁻²⁴	Heart Left Ventricle	4.6 10 ⁻⁰⁸
rs5760061 (r ² : 1)	SMARCB1	22	MMP11	22	3.3 10 ⁻¹⁶	Heart Atrial Appendage	4.6 10 ⁻⁰⁸
rs5760061 (r ² : 1)	SMARCB1	22	SMARCB1	22	7.3 10 ⁻²²	Heart Left Ventricle	4.6 10 ⁻⁰⁸
rs5760061 (r ² : 1)	SMARCB1	22	SMARCB1	22	7.5 10 ⁻¹⁷	Heart Atrial Appendage	4.6 10 ⁻⁰⁸
rs5760061 (r ² : 1)	SMARCB1	22	SMARCB1	22	6.1 10 ⁻¹⁸	Skeletal muscle	4.6 10 ⁻⁰⁸
rs5760061 (r ² : 1)	SMARCB1	22	VPREB3	22	1.9 10 ⁻⁸	Heart Left Ventricle	4.6 10 ⁻⁰⁸
rs5760061 (r ² : 1)	SMARCB1	22	VPREB3	22	1.1 10 ⁻¹⁷	Skeletal muscle	4.6 10 ⁻⁰⁸
rs5760061 (r ² : 1)	SMARCB1	22	DERL3	22	1.1 10 ⁻⁴	Skeletal muscle	4.6 10 ⁻⁰⁸
rs2267039 (r ² : 1)	SMARCB1	22	MMP11	22	2.5 10 ⁻²⁴	Heart Left Ventricle	3.9 10 ⁻⁰⁸

rs2267039 (r ² : 1)	SMARCB1	22	MMP11	22	3.3 10 ⁻¹⁶	Heart Atrial Appendage	3.9 10 ⁻⁰⁸
rs2267039 (r ² : 1)	SMARCB1	22	SMARCB1	22	7.3 10 ⁻²²	Heart Left Ventricle	3.9 10 ⁻⁰⁸
rs2267039 (r ² : 1)	SMARCB1	22	SMARCB1	22	7.5 10 ⁻¹⁷	Heart Atrial Appendage	3.9 10 ⁻⁰⁸
rs2267039 (r ² : 1)	SMARCB1	22	SMARCB1	22	3.0 10 ⁻¹⁸	Skeletal muscle	3.9 10 ⁻⁰⁸
rs2267039 (r ² : 1)	SMARCB1	22	VPREB3	22	1.9 10 ⁻⁸	Heart Left Ventricle	3.9 10 ⁻⁰⁸
rs2267039 (r ² : 1)	SMARCB1	22	VPREB3	22	3.7 10 ⁻¹⁸	Skeletal muscle	3.9 10 ⁻⁰⁸
rs2267039 (r ² : 1)	SMARCB1	22	DERL3	22	1.2 10 ⁻⁶	Skeletal muscle	3.9 10 ⁻⁰⁸
rs2267038 (r ² : 0.92)	SMARCB1	22	MMP11	22	2.6 10 ⁻²¹	Heart Left Ventricle	3.7 10 ⁻⁰⁸
rs2267038 (r ² : 0.92)	SMARCB1	22	MMP11	22	5.1 10 ⁻¹⁴	Heart Atrial Appendage	3.7 10 ⁻⁰⁸
rs2267038 (r ² : 0.92)	SMARCB1	22	SMARCB1	22	2.1 10 ⁻²⁴	Heart Left Ventricle	3.7 10 ⁻⁰⁸
rs2267038 (r ² : 0.92)	SMARCB1	22	SMARCB1	22	2.0 10 ⁻²⁰	Heart Atrial Appendage	3.7 10 ⁻⁰⁸
rs2267038 (r ² : 0.92)	SMARCB1	22	SMARCB1	22	4.2 10 ⁻²³	Skeletal muscle	3.7 10 ⁻⁰⁸
rs2267038 (r ² : 0.92)	SMARCB1	22	VPREB3	22	8.9 10 ⁻⁹	Heart Left Ventricle	3.7 10 ⁻⁰⁸
rs2267038 (r ² : 0.92)	SMARCB1	22	VPREB3	22	3.2 10 ⁻⁶	Heart Atrial Appendage	3.7 10 ⁻⁰⁸
rs2267038 (r ² : 0.92)	SMARCB1	22	VPREB3	22	1.8 10 ⁻²⁰	Skeletal muscle	3.7 10 ⁻⁰⁸
rs2267038 (r ² : 0.92)	SMARCB1	22	DERL3	22	5.4 10 ⁻⁶	Skeletal muscle	3.7 10 ⁻⁰⁸
rs6003909 (r ² : 0.76)	DERL3	22	MMP11	22	2.5 10 ⁻¹⁴	Heart Left Ventricle	6.3 10 ⁻⁰⁸
rs6003909 (r ² : 0.76)	DERL3	22	MMP11	22	5.0 10 ⁻¹⁰	Heart Atrial Appendage	6.3 10 ⁻⁰⁸
rs6003909 (r ² : 0.76)	DERL3	22	SMARCB1	22	3.5 10 ⁻¹⁴	Heart Left Ventricle	6.3 10 ⁻⁰⁸
rs6003909 (r ² : 0.76)	DERL3	22	SMARCB1	22	5.4 10 ⁻¹⁷	Heart Atrial Appendage	6.3 10 ⁻⁰⁸
rs6003909 (r ² : 0.76)	DERL3	22	SMARCB1	22	1.1 10 ⁻¹⁸	Skeletal muscle	6.3 10 ⁻⁰⁸
rs6003909 (r ² : 0.76)	DERL3	22	VPREB3	22	3.0 10 ⁻⁷	Heart Left Ventricle	6.3 10 ⁻⁰⁸
rs6003909 (r ² : 0.76)	DERL3	22	VPREB3	22	4.5 10 ⁻¹³	Skeletal muscle	6.3 10 ⁻⁰⁸
rs6003909 (r ² : 0.76)	DERL3	22	DERL3	22	1.4 10 ⁻⁸	Skeletal muscle	6.3 10 ⁻⁰⁸
rs80135378 (r ² : 0.73)	SMARCB1	22	MMP11	22	5.6 10 ⁻²¹	Heart Left Ventricle	1.8 10 ⁻⁰⁵
rs80135378 (r ² : 0.73)	SMARCB1	22	MMP11	22	1.1 10 ⁻¹⁴	Heart Atrial Appendage	1.8 10 ⁻⁰⁵

rs80135378 (r ² : 0.73)	SMARCB1	22	SMARCB1	22	2.2 10 ⁻²⁵	Heart Left Ventricle	1.8 10 ⁻⁰⁵
rs80135378 (r ² : 0.73)	SMARCB1	22	SMARCB1	22	5.4 10 ⁻¹⁷	Heart Atrial Appendage	1.8 10 ⁻⁰⁵
rs80135378 (r ² : 0.73)	SMARCB1	22	SMARCB1	22	2.0 10 ⁻²⁴	Skeletal muscle	1.8 10 ⁻⁰⁵
rs80135378 (r ² : 0.73)	SMARCB1	22	VPREB3	22	8.3 10 ⁻¹⁰	Heart Left Ventricle	1.8 10 ⁻⁰⁵
rs80135378 (r ² : 0.73)	SMARCB1	22	VPREB3	22	4.5 10 ⁻¹³	Heart Atrial Appendage	1.8 10 ⁻⁰⁵
rs80135378 (r ² : 0.73)	SMARCB1	22	VPREB3	22	3.9 10 ⁻¹⁸	Skeletal muscle	1.8 10 ⁻⁰⁵
rs9612464 (r ² : 0.73)	SMARCB1	22	MMP11	22	5.6 10 ⁻²¹	Heart Left Ventricle	1.0 10 ⁻⁰⁵
rs9612464 (r ² : 0.73)	SMARCB1	22	MMP11	22	1.1 10 ⁻¹⁴	Heart Atrial Appendage	1.0 10 ⁻⁰⁵
rs9612464 (r ² : 0.73)	SMARCB1	22	SMARCB1	22	2.2 10 ⁻²⁵	Heart Left Ventricle	1.0 10 ⁻⁰⁵
rs9612464 (r ² : 0.73)	SMARCB1	22	SMARCB1	22	7.7 10 ⁻²¹	Heart Atrial Appendage	1.0 10 ⁻⁰⁵
rs9612464 (r ² : 0.73)	SMARCB1	22	SMARCB1	22	2.0 10 ⁻²⁴	Skeletal muscle	1.0 10 ⁻⁰⁵
rs9612464 (r ² : 0.73)	SMARCB1	22	VPREB3	22	8.3 10 ⁻¹⁰	Heart Left Ventricle	1.0 10 ⁻⁰⁵
rs9612464 (r ² : 0.73)	SMARCB1	22	VPREB3	22	8.4 10 ⁻⁶	Heart Atrial Appendage	1.0 10 ⁻⁰⁵
rs9612464 (r ² : 0.73)	SMARCB1	22	VPREB3	22	3.9 10 ⁻¹⁸	Skeletal muscle	1.0 10 ⁻⁰⁵
rs17003930 (r ² : 0.73)	SMARCB1	22	MMP11	22	1.7 10 ⁻¹⁴	Heart Left Ventricle	1.9 10 ⁻⁰⁵
rs17003930 (r ² : 0.73)	SMARCB1	22	MMP11	22	1.3 10 ⁻¹¹	Heart Atrial Appendage	1.9 10 ⁻⁰⁵
rs17003930 (r ² : 0.73)	SMARCB1	22	SMARCB1	22	3.0 10 ⁻¹⁶	Heart Left Ventricle	1.9 10 ⁻⁰⁵
rs17003930 (r ² : 0.73)	SMARCB1	22	SMARCB1	22	1.3 10 ⁻¹⁶	Heart Atrial Appendage	1.9 10 ⁻⁰⁵
rs17003930 (r ² : 0.73)	SMARCB1	22	SMARCB1	22	1.6 10 ⁻¹⁹	Skeletal muscle	1.9 10 ⁻⁰⁵
rs17003930 (r ² : 0.73)	SMARCB1	22	VPREB3	22	3.8 10 ⁻¹²	Heart Left Ventricle	1.9 10 ⁻⁰⁵
rs17003930 (r ² : 0.73)	SMARCB1	22	VPREB3	22	5.0 10 ⁻⁶	Heart Atrial Appendage	1.9 10 ⁻⁰⁵
rs17003930 (r ² : 0.73)	SMARCB1	22	VPREB3	22	3.4 10 ⁻¹⁷	Skeletal muscle	1.9 10 ⁻⁰⁵
rs17003930 (r ² : 0.73)	SMARCB1	22	DERL3	22	2.8 10 ⁻⁵	Skeletal muscle	1.9 10 ⁻⁰⁵
rs6003895 (r ² : 0.73)	SMARCB1	22	MMP11	22	5.6 10 ⁻²¹	Heart Left Ventricle	9.6 10 ⁻⁰⁶
rs6003895 (r ² : 0.73)	SMARCB1	22	MMP11	22	1.1 10 ⁻¹⁴	Heart Atrial Appendage	9.6 10 ⁻⁰⁶
rs6003895 (r ² : 0.73)	SMARCB1	22	SMARCB1	22	2.2 10 ⁻²⁵	Heart Left Ventricle	9.6 10 ⁻⁰⁶

rs6003895 (r ² : 0.73)	SMARCB1	22	SMARCB1	22	7.7 10 ⁻²¹	Heart Atrial Appendage	9.6 10 ⁻⁰⁶
rs6003895 (r ² : 0.73)	SMARCB1	22	SMARCB1	22	2.0 10 ⁻²⁴	Skeletal muscle	9.6 10 ⁻⁰⁶
rs6003895 (r ² : 0.73)	SMARCB1	22	VPREB3	22	8.3 10 ⁻¹⁰	Heart Left Ventricle	9.6 10 ⁻⁰⁶
rs6003895 (r ² : 0.73)	SMARCB1	22	VPREB3	22	8.4 10 ⁻⁶	Heart Atrial Appendage	9.6 10 ⁻⁰⁶
rs6003895 (r ² : 0.73)	SMARCB1	22	VPREB3	22	3.9 10 ⁻¹⁸	Skeletal muscle	9.6 10 ⁻⁰⁶
rs8140489 (r ² : 0.73)	SMARCB1	22	MMP11	22	5.6 10 ⁻²¹	Heart Left Ventricle	9.5 10 ⁻⁰⁶
rs8140489 (r ² : 0.73)	SMARCB1	22	MMP11	22	1.1 10 ⁻¹⁴	Heart Atrial Appendage	9.5 10 ⁻⁰⁶
rs8140489 (r ² : 0.73)	SMARCB1	22	SMARCB1	22	2.2 10 ⁻²⁵	Heart Left Ventricle	9.5 10 ⁻⁰⁶
rs8140489 (r ² : 0.73)	SMARCB1	22	SMARCB1	22	7.7 10 ⁻²¹	Heart Atrial Appendage	9.5 10 ⁻⁰⁶
rs8140489 (r ² : 0.73)	SMARCB1	22	SMARCB1	22	2.0 10 ⁻²⁴	Skeletal muscle	9.5 10 ⁻⁰⁶
rs8140489 (r ² : 0.73)	SMARCB1	22	VPREB3	22	8.3 10 ⁻¹⁰	Heart Left Ventricle	9.5 10 ⁻⁰⁶
rs8140489 (r ² : 0.73)	SMARCB1	22	VPREB3	22	8.4 10 ⁻⁶	Heart Atrial Appendage	9.5 10 ⁻⁰⁶
rs8140489 (r ² : 0.73)	SMARCB1	22	VPREB3	22	3.9 10 ⁻¹⁸	Skeletal muscle	9.5 10 ⁻⁰⁶
rs6003898 (r ² : 0.73)	SMARCB1	22	MMP11	22	5.6 10 ⁻²¹	Heart Left Ventricle	9.2 10 ⁻⁰⁶
rs6003898 (r ² : 0.73)	SMARCB1	22	MMP11	22	1.1 10 ⁻¹⁴	Heart Atrial Appendage	9.2 10 ⁻⁰⁶
rs6003898 (r ² : 0.73)	SMARCB1	22	SMARCB1	22	2.2 10 ⁻²⁵	Heart Left Ventricle	9.2 10 ⁻⁰⁶
rs6003898 (r ² : 0.73)	SMARCB1	22	SMARCB1	22	7.7 10 ⁻²¹	Heart Atrial Appendage	9.2 10 ⁻⁰⁶
rs6003898 (r ² : 0.73)	SMARCB1	22	SMARCB1	22	2.0 10 ⁻²⁴	Skeletal muscle	9.2 10 ⁻⁰⁶
rs6003898 (r ² : 0.73)	SMARCB1	22	VPREB3	22	8.3 10 ⁻¹⁰	Heart Left Ventricle	9.2 10 ⁻⁰⁶
rs6003898 (r ² : 0.73)	SMARCB1	22	VPREB3	22	8.4 10 ⁻⁶	Heart Atrial Appendage	9.2 10 ⁻⁰⁶
rs6003898 (r ² : 0.73)	SMARCB1	22	VPREB3	22	3.9 10 ⁻¹⁸	Skeletal muscle	9.2 10 ⁻⁰⁶
rs6003900 (r ² : 0.73)	SMARCB1	22	MMP11	22	5.6 10 ⁻²¹	Heart Left Ventricle	8.8 10 ⁻⁰⁶
rs6003900 (r ² : 0.73)	SMARCB1	22	MMP11	22	1.1 10 ⁻¹⁴	Heart Atrial Appendage	8.8 10 ⁻⁰⁶
rs6003900 (r ² : 0.73)	SMARCB1	22	SMARCB1	22	2.2 10 ⁻²⁵	Heart Left Ventricle	8.8 10 ⁻⁰⁶
rs6003900 (r ² : 0.73)	SMARCB1	22	SMARCB1	22	7.7 10 ⁻²¹	Heart Atrial Appendage	8.8 10 ⁻⁰⁶
rs6003900 (r ² : 0.73)	SMARCB1	22	SMARCB1	22	9.7 10 ⁻²⁵	Skeletal muscle	8.8 10 ⁻⁰⁶

rs6003900 (r^2 : 0.73)	SMARCB1	22	VPREB3	22	$8.3 \cdot 10^{-10}$	Heart Left Ventricle	$8.8 \cdot 10^{-06}$
rs6003900 (r^2 : 0.73)	SMARCB1	22	VPREB3	22	$8.4 \cdot 10^{-6}$	Heart Atrial Appendage	$8.8 \cdot 10^{-06}$
rs6003900 (r^2 : 0.73)	SMARCB1	22	VPREB3	22	$4.3 \cdot 10^{-18}$	Skeletal muscle	$8.8 \cdot 10^{-06}$
rs6003904 (r^2 : 0.73)	SMARCB1	22	MMP11	22	$5.6 \cdot 10^{-21}$	Heart Left Ventricle	$8.8 \cdot 10^{-06}$
rs6003904 (r^2 : 0.73)	SMARCB1	22	MMP11	22	$1.1 \cdot 10^{-14}$	Heart Atrial Appendage	$8.8 \cdot 10^{-06}$
rs6003904 (r^2 : 0.73)	SMARCB1	22	SMARCB1	22	$2.2 \cdot 10^{-25}$	Heart Left Ventricle	$8.8 \cdot 10^{-06}$
rs6003904 (r^2 : 0.73)	SMARCB1	22	SMARCB1	22	$7.7 \cdot 10^{-21}$	Heart Atrial Appendage	$8.8 \cdot 10^{-06}$
rs6003904 (r^2 : 0.73)	SMARCB1	22	SMARCB1	22	$9.7 \cdot 10^{-25}$	Skeletal muscle	$8.8 \cdot 10^{-06}$
rs6003904 (r^2 : 0.73)	SMARCB1	22	VPREB3	22	$8.3 \cdot 10^{-10}$	Heart Left Ventricle	$8.8 \cdot 10^{-06}$
rs6003904 (r^2 : 0.73)	SMARCB1	22	VPREB3	22	$8.4 \cdot 10^{-6}$	Heart Atrial Appendage	$8.8 \cdot 10^{-06}$
rs6003904 (r^2 : 0.73)	SMARCB1	22	VPREB3	22	$4.3 \cdot 10^{-18}$	Skeletal muscle	$8.8 \cdot 10^{-06}$
rs6003905 (r^2 : 0.73)	SMARCB1	22	MMP11	22	$5.6 \cdot 10^{-21}$	Heart Left Ventricle	$8.1 \cdot 10^{-06}$
rs6003905 (r^2 : 0.73)	SMARCB1	22	MMP11	22	$1.1 \cdot 10^{-14}$	Heart Atrial Appendage	$8.1 \cdot 10^{-06}$
rs6003905 (r^2 : 0.73)	SMARCB1	22	SMARCB1	22	$2.2 \cdot 10^{-25}$	Heart Left Ventricle	$8.1 \cdot 10^{-06}$
rs6003905 (r^2 : 0.73)	SMARCB1	22	SMARCB1	22	$7.7 \cdot 10^{-21}$	Heart Atrial Appendage	$8.1 \cdot 10^{-06}$
rs6003905 (r^2 : 0.73)	SMARCB1	22	SMARCB1	22	$9.7 \cdot 10^{-25}$	Skeletal muscle	$8.1 \cdot 10^{-06}$
rs6003905 (r^2 : 0.73)	SMARCB1	22	VPREB3	22	$8.3 \cdot 10^{-10}$	Heart Left Ventricle	$8.1 \cdot 10^{-06}$
rs6003905 (r^2 : 0.73)	SMARCB1	22	VPREB3	22	$8.4 \cdot 10^{-6}$	Heart Atrial Appendage	$8.1 \cdot 10^{-06}$
rs6003905 (r^2 : 0.73)	SMARCB1	22	VPREB3	22	$4.3 \cdot 10^{-18}$	Skeletal muscle	$8.1 \cdot 10^{-06}$
rs17003983 (r^2 : 0.73)	SMARCB1	22	MMP11	22	$1.5 \cdot 10^{-15}$	Heart Left Ventricle	$7.3 \cdot 10^{-06}$
rs17003983 (r^2 : 0.73)	SMARCB1	22	MMP11	22	$1.2 \cdot 10^{-11}$	Heart Atrial Appendage	$7.3 \cdot 10^{-06}$
rs17003983 (r^2 : 0.73)	SMARCB1	22	SMARCB1	22	$1.3 \cdot 10^{-17}$	Heart Left Ventricle	$7.3 \cdot 10^{-06}$
rs17003983 (r^2 : 0.73)	SMARCB1	22	SMARCB1	22	$2.5 \cdot 10^{-16}$	Heart Atrial Appendage	$7.3 \cdot 10^{-06}$
rs17003983 (r^2 : 0.73)	SMARCB1	22	SMARCB1	22	$3.5 \cdot 10^{-23}$	Skeletal muscle	$7.3 \cdot 10^{-06}$
rs17003983 (r^2 : 0.73)	SMARCB1	22	VPREB3	22	$1.3 \cdot 10^{-12}$	Heart Left Ventricle	$7.3 \cdot 10^{-06}$
rs17003983 (r^2 : 0.73)	SMARCB1	22	VPREB3	22	$2.7 \cdot 10^{-6}$	Heart Atrial Appendage	$7.3 \cdot 10^{-06}$

rs17003983 (r^2 : 0.73)	SMARCB1	22	VPREB3	22	$3.5 \cdot 10^{-17}$	Skeletal muscle	$7.3 \cdot 10^{-06}$
rs17003983 (r^2 : 0.73)	SMARCB1	22	DERL3	22	$1.7 \cdot 10^{-6}$	Skeletal muscle	$7.3 \cdot 10^{-06}$
rs8138435 (r^2 : 0.73)	SMARCB1	22	MMP11	22	$5.6 \cdot 10^{-21}$	Heart Left Ventricle	$8.8 \cdot 10^{-06}$
rs8138435 (r^2 : 0.73)	SMARCB1	22	MMP11	22	$1.1 \cdot 10^{-14}$	Heart Atrial Appendage	$8.8 \cdot 10^{-06}$
rs8138435 (r^2 : 0.73)	SMARCB1	22	SMARCB1	22	$2.2 \cdot 10^{-25}$	Heart Left Ventricle	$8.8 \cdot 10^{-06}$
rs8138435 (r^2 : 0.73)	SMARCB1	22	SMARCB1	22	$7.7 \cdot 10^{-21}$	Heart Atrial Appendage	$8.8 \cdot 10^{-06}$
rs8138435 (r^2 : 0.73)	SMARCB1	22	SMARCB1	22	$9.7 \cdot 10^{-25}$	Skeletal muscle	$8.8 \cdot 10^{-06}$
rs8138435 (r^2 : 0.73)	SMARCB1	22	VPREB3	22	$8.3 \cdot 10^{-10}$	Heart Left Ventricle	$8.8 \cdot 10^{-06}$
rs8138435 (r^2 : 0.73)	SMARCB1	22	VPREB3	22	$8.4 \cdot 10^{-6}$	Heart Atrial Appendage	$8.8 \cdot 10^{-06}$
rs8138435 (r^2 : 0.73)	SMARCB1	22	VPREB3	22	$4.3 \cdot 10^{-18}$	Skeletal muscle	$8.8 \cdot 10^{-06}$
rs8138827 (r^2 : 0.73)	SMARCB1	22	MMP11	22	$5.6 \cdot 10^{-21}$	Heart Left Ventricle	$8.8 \cdot 10^{-06}$
rs8138827 (r^2 : 0.73)	SMARCB1	22	MMP11	22	$1.1 \cdot 10^{-14}$	Heart Atrial Appendage	$8.8 \cdot 10^{-06}$
rs8138827 (r^2 : 0.73)	SMARCB1	22	SMARCB1	22	$2.2 \cdot 10^{-25}$	Heart Left Ventricle	$8.8 \cdot 10^{-06}$
rs8138827 (r^2 : 0.73)	SMARCB1	22	SMARCB1	22	$7.7 \cdot 10^{-21}$	Heart Atrial Appendage	$8.8 \cdot 10^{-06}$
rs8138827 (r^2 : 0.73)	SMARCB1	22	SMARCB1	22	$9.7 \cdot 10^{-25}$	Skeletal muscle	$8.8 \cdot 10^{-06}$
rs8138827 (r^2 : 0.73)	SMARCB1	22	VPREB3	22	$8.3 \cdot 10^{-10}$	Heart Left Ventricle	$8.8 \cdot 10^{-06}$
rs8138827 (r^2 : 0.73)	SMARCB1	22	VPREB3	22	$8.4 \cdot 10^{-6}$	Heart Atrial Appendage	$8.8 \cdot 10^{-06}$
rs8138827 (r^2 : 0.73)	SMARCB1	22	VPREB3	22	$4.3 \cdot 10^{-18}$	Skeletal muscle	$8.8 \cdot 10^{-06}$
rs2267045 (r^2 : 0.73)	SMARCB1	22	MMP11	22	$6.1 \cdot 10^{-23}$	Heart Left Ventricle	$8.5 \cdot 10^{-06}$
rs2267045 (r^2 : 0.73)	SMARCB1	22	MMP11	22	$2.4 \cdot 10^{-15}$	Heart Atrial Appendage	$8.5 \cdot 10^{-06}$
rs2267045 (r^2 : 0.73)	SMARCB1	22	SMARCB1	22	$3.2 \cdot 10^{-26}$	Heart Left Ventricle	$8.5 \cdot 10^{-06}$
rs2267045 (r^2 : 0.73)	SMARCB1	22	SMARCB1	22	$4.7 \cdot 10^{-21}$	Heart Atrial Appendage	$8.5 \cdot 10^{-06}$
rs2267045 (r^2 : 0.73)	SMARCB1	22	SMARCB1	22	$1.9 \cdot 10^{-24}$	Skeletal muscle	$8.5 \cdot 10^{-06}$
rs2267045 (r^2 : 0.73)	SMARCB1	22	VPREB3	22	$2.0 \cdot 10^{-9}$	Heart Left Ventricle	$8.5 \cdot 10^{-06}$
rs2267045 (r^2 : 0.73)	SMARCB1	22	VPREB3	22	$2.2 \cdot 10^{-5}$	Heart Atrial Appendage	$8.5 \cdot 10^{-06}$
rs2267045 (r^2 : 0.73)	SMARCB1	22	VPREB3	22	$3.3 \cdot 10^{-18}$	Skeletal muscle	$8.5 \cdot 10^{-06}$

rs1128127 (r ² : 0.73)	SMARCB1	22	MMP11	22	5.6 10 ⁻²¹	Heart Left Ventricle	1.4 10 ⁻⁰⁵
rs1128127 (r ² : 0.73)	SMARCB1	22	MMP11	22	1.1 10 ⁻¹⁴	Heart Atrial Appendage	1.4 10 ⁻⁰⁵
rs1128127 (r ² : 0.73)	SMARCB1	22	SMARCB1	22	2.2 10 ⁻²⁵	Heart Left Ventricle	1.4 10 ⁻⁰⁵
rs1128127 (r ² : 0.73)	SMARCB1	22	SMARCB1	22	7.7 10 ⁻²¹	Heart Atrial Appendage	1.4 10 ⁻⁰⁵
rs1128127 (r ² : 0.73)	SMARCB1	22	SMARCB1	22	4.9 10 ⁻²⁴	Skeletal muscle	1.4 10 ⁻⁰⁵
rs1128127 (r ² : 0.73)	SMARCB1	22	VPREB3	22	8.3 10 ⁻¹⁰	Heart Left Ventricle	1.4 10 ⁻⁰⁵
rs1128127 (r ² : 0.73)	SMARCB1	22	VPREB3	22	8.4 10 ⁻⁶	Heart Atrial Appendage	1.4 10 ⁻⁰⁵
rs1128127 (r ² : 0.73)	SMARCB1	22	VPREB3	22	1.2 10 ⁻¹⁷	Skeletal muscle	1.4 10 ⁻⁰⁵
rs9612485 (r ² : 0.73)	SMARCB1	22	MMP11	22	5.6 10 ⁻²¹	Heart Left Ventricle	1.5 10 ⁻⁰⁵
rs9612485 (r ² : 0.73)	SMARCB1	22	MMP11	22	1.1 10 ⁻¹⁴	Heart Atrial Appendage	1.5 10 ⁻⁰⁵
rs9612485 (r ² : 0.73)	SMARCB1	22	SMARCB1	22	2.2 10 ⁻²⁵	Heart Left Ventricle	1.5 10 ⁻⁰⁵
rs9612485 (r ² : 0.73)	SMARCB1	22	SMARCB1	22	7.7 10 ⁻²¹	Heart Atrial Appendage	1.5 10 ⁻⁰⁵
rs9612485 (r ² : 0.73)	SMARCB1	22	SMARCB1	22	4.9 10 ⁻²⁴	Skeletal muscle	1.5 10 ⁻⁰⁵
rs9612485 (r ² : 0.73)	SMARCB1	22	VPREB3	22	8.3 10 ⁻¹⁰	Heart Left Ventricle	1.5 10 ⁻⁰⁵
rs9612485 (r ² : 0.73)	SMARCB1	22	VPREB3	22	8.4 10 ⁻⁶	Heart Atrial Appendage	1.5 10 ⁻⁰⁵
rs9612485 (r ² : 0.73)	SMARCB1	22	VPREB3	22	1.2 10 ⁻¹⁷	Skeletal muscle	1.5 10 ⁻⁰⁵
rs11703971 (r ² : 0.73)	SMARCB1	22	MMP11	22	5.6 10 ⁻²¹	Heart Left Ventricle	1.8 10 ⁻⁰⁵
rs11703971 (r ² : 0.73)	SMARCB1	22	MMP11	22	1.1 10 ⁻¹⁴	Heart Atrial Appendage	1.8 10 ⁻⁰⁵
rs11703971 (r ² : 0.73)	SMARCB1	22	SMARCB1	22	2.2 10 ⁻²⁵	Heart Left Ventricle	1.8 10 ⁻⁰⁵
rs11703971 (r ² : 0.73)	SMARCB1	22	SMARCB1	22	7.7 10 ⁻²¹	Heart Atrial Appendage	1.8 10 ⁻⁰⁵
rs11703971 (r ² : 0.73)	SMARCB1	22	SMARCB1	22	4.9 10 ⁻²⁴	Skeletal muscle	1.8 10 ⁻⁰⁵
rs11703971 (r ² : 0.73)	SMARCB1	22	VPREB3	22	8.3 10 ⁻¹⁰	Heart Left Ventricle	1.8 10 ⁻⁰⁵
rs11703971 (r ² : 0.73)	SMARCB1	22	VPREB3	22	8.4 10 ⁻⁶	Heart Atrial Appendage	1.8 10 ⁻⁰⁵
rs11703971 (r ² : 0.73)	SMARCB1	22	VPREB3	22	1.2 10 ⁻¹⁷	Skeletal muscle	1.8 10 ⁻⁰⁵

Table 4: SNP annotation. This excel table is given in a supplemental excel file.